

CIHR Institute of Gender and Health	Certificate	Core Competency Module for Sex and Gender in Primary Data Collection with Humans	2018/6
University of British Columbia	Certificate	Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans Course on Research Ethics (TCPS 2: CORE)	2016/2
University of British Columbia, International Program for the Scholarship of Educational Leadership	Certificate	Scholarship of Educational Leadership on Curriculum and Pedagogy in Higher Education	2015/9 - 2016/5
University of British Columbia, Faculty of Medicine	Certificate	Relationship with Industry Training Module	2015/6
University of British Columbia Centre for Teaching, Learning and Technology	Certificate	Faculty Instructional Skills Workshop	2015/7
University of Aberdeen, UK	Certificate	Using Discrete Choice Experiments in Health Economics: Theoretical and Practical Issues	2011/8
The University of York/The University of Glasgow, UK	Certificate	Advanced Modelling Methods for Health Economic Evaluation	2010/11
Oxford Brookes University, UK	Certificate	Tutoring for distance learning	2010/4
The University of York, UK.	Certificate	Economic evaluations and economic evidence in healthcare: finding information to inform technology assessments and economic models	2008/3
University of Manchester, UK	Certificate	Research Governance	2008/7
Manchester Child Medicine Network, Manchester, UK	Certificate	International Conference on Harmonisation (ICH) Good Clinical Practice	2008/6
University of Reading	Certificate	Longitudinal Modelling	2008/4
University of Cambridge, MRC Biostatistics Unit, UK	Certificate	Statistical Methods for Health Economic Evaluation	2004/5

6. **EMPLOYMENT RECORD**

(a) ***Prior to coming to UBC***

University, Company or Organization	Rank or Title	Dates
University of Manchester, Manchester Centre for Health Economics	Senior Research Fellow	2013/8 – 2014/8
University of Manchester, Manchester Centre for Health Economics	Research Fellow	2010/7 - 2013/8
University of Manchester, National Primary Care Research and Development Centre	Research Associate	2009/2 - 2010/7
University of Manchester, Arthritis UK Epidemiology Unit	Research Assistant	2002/8 – 2009/2

(b) ***At UBC***

Rank or Title	Dates
Associate Professor, Faculty of Pharmaceutical Sciences	2019/7 - present
Assistant Professor, Faculty of Pharmaceutical Sciences	2014/8 - 2019/6

(c) **Date of granting of tenure at U.B.C.:** 1st July 2019

(d) **Other Academic Affiliations**

Rank or Title	Dates
Faculty Associate, Institute for Resources, Environment and Sustainability (IRES), UBC	2021/12 - present
Member, Planetary Health Lab, UBC	2021/4 - present
Affiliate Faculty, School of Population and Public Health, Faculty of Medicine, UBC	2020/10 - present
Affiliate, Neuroethics Canada, UBC	2018/9 - present
Affiliate Scientist, Arthritis Research Centre of Canada, Richmond, British Columbia	2016/9 - present
Scientist, Centre for Health Evaluation and Outcomes Sciences (CHEOS), Providence Health Care Research Institute, Vancouver, British Columbia.	2014/8 - present
Honorary Senior Research Fellow, Manchester Centre for Health Economics, University of Manchester, UK	2014/8 - present

7. LEAVES OF ABSENCE

1st January 2023 – 31st December 2023: Sabbatical leave

8. TEACHING

(a) *Areas of special interest and accomplishments*

I have received two salary awards: a Michael Smith Foundation for Health Research Scholar Award (2017) and an Arthritis Society Young Investigator Salary Award (2016). These peer-reviewed, competitive salary awards intend to facilitate and promote my research career. As such, both awards stipulated limitations to the time committed to teaching between 2017 and 2022 so that I could focus on developing my research program. Despite these restrictions, I continued to teach as much as these awards permitted. In doing so, I co-developed two new courses (PPHC/PHRM100 and PHAR205) for the new Entry-to-Practice PharmD (E2P Pharmd) and Bachelors of Pharmaceutical Sciences (BPSc) programs in the faculty, redesigned a course as an elective for the new Entry-to-Practice PharmD program, and continued teaching at graduate and undergraduate levels. Between January 1st 2023 and December 31st 2023 I was on sabbatical and so did not teach during that period.

(b) *Courses Taught at UBC*

Session	Course Number	Scheduled Hours	Class Size	Hours Taught			
				Lectures	Tutorials	Labs	Other
2024W1	PHRM100	21	224	11.5			
2023W2	PHAR204	39	53	1.5			
2023W2	PHAR205	39	53	13	6		
2022W1	PHRM100	22	222	13			
2021W2	PHAR205	39	31	16			
2021W2	PHRM332	39	12	13.5	7.5		
2021W1	PHRM100	24	226	12			
2020W2	PHAR 548/648 (G)	1	35	1			
2020W2	PHRM332	39	5	15	4.5		
2020W1	PHRM100	24	228	9			
2019W1	PHRM100	24	229	8	10.5 (IA)		
2018W2	SPPH514(G)	2	14	2			
2018W1	PHRM100	24	228	8	10.5 (IA)		
2018W1	PHAR456	39	11	16	8		
2017W1	PHRM100	24	225	6	10.5 (IA)		
2017W1	PHAR456	39	23	21	9		
2016W2	PHAR456	39	22	18	9		
2016W2	PHAR506	39	6	10.5	3		
2016W1	PHRM100	24	232	7	10.5 (IA)		
2016W1	PHAR506	39	6	7.5	3		
2015W2	PHAR456	39	3	16	4		
2015W2	PHAR506	39	10	15	5		
2015W1	PHAR506	39	8	15	1.5		
2015W1	PHRM100	24	224	4	10.5 (IA)		
2014W2	PHAR506	39	12	7	3		
2014W2	PHAR456	39	12	7	1		
2014W1	PHAR400 (G)	39	60	2			

G = Guest lecture; IA= Interactive activities

International Guest Lectures at the University of California, Davis, USA

Session	Course Number	Scheduled Hours	Class Size	Hours Taught			
				Lectures	Tutorials	Labs	Other
2022W2	SPH276 (Critical Assessment in Health Policy & Economics)	39	12	3			
<i>Session title: Value judgements in decision modelling – implications for equity</i>							

Guest Lectures at Simon Fraser University, Vancouver

Session	Course Number	Scheduled Hours	Class Size	Hours Taught			
				Lectures	Tutorials	Labs	Other
2018S1	HSCI306 (Principles of Health Economics)	39	63	3			
2016W1	HSCI306 (Principles of Health Economics)	39	60	3			

(c) Graduate Students Supervised Primary or Co-supervisor

MSc and PhD Students Supervised

Total 17: 4 current, 13 complete
 PhD: Total 9: 3 current, 6 complete
 MSc: Total 8: 1 current, 7 complete

Student Name	University	Program Type	Year		Supervisory Role
			Start	Finish	
Nazafarin Esfandiari	University of British Columbia	MSc	2024/9	Active	Supervisor
<i>Thesis title: Assessing Environmental Impact in Health Economic Evaluations/Health Technology Assessment</i>					
HaoHung Dang	University of British Columbia	MSc	2022/9	2024/6	Supervisor
<i>Thesis title: How a biosimilar switching policy impacted healthcare resource utilization and cost in British Columbia</i>					
Maggie Miao Yu	University of British Columbia	MSc	2022/9	2024/6	Co-Supervisor
<i>Title: Evaluating the value of patient-reported outcome measures in predicting unplanned hospital readmission or mortality</i>					
Blair MacDonald	University of British Columbia	PhD	2023/5	Active	Co-supervisor
<i>Thesis title: A preference heterogeneity and economic evaluation informed approach to develop a focused and compelling case for shared decision-making</i>					
Glory Apantaku ¹	University of British Columbia	PhD	2021/9	Active	Supervisor
<i>Thesis title: Adapting to climate impacts: a health-based perspective</i>					
Megan Thomas ^{2,3}	University of British Columbia	PhD	2021/9	Active	Co-supervisor
<i>Thesis title: Assessing equity considerations in the care of patients with inflammatory arthritis</i>					
Alison McClean ⁴	University of British Columbia	MSc	2020/9	2022/9	Co-supervisor
<i>Thesis title: Evaluating biosimilars uptake and policies in Canada</i>					
Norma Biln	University of British Columbia	PhD	2018/9	2024/7	Supervisor
<i>Thesis title: Improving referrals to rheumatologists for patients with inflammatory arthritis</i>					
<ul style="list-style-type: none"> <i>Thesis nominated for CAGS/PROQUEST Distinguished Dissertation Award for Canadian doctoral dissertations that make unusually significant and original contributions to their academic field</i> 					
Ross Duncan ⁵	University of British Columbia	MSc	2017/9	2019/8	Supervisor
<i>Thesis title: Evaluating the impact on access of the introduction of nurse-supported care for people with complex rheumatic diseases in British Columbia</i>					
Rebecca Metcalfe	University of British Columbia	PhD	2016/9	2021/7	Co-supervisor
<i>Thesis title: Patient-oriented research to support decision-making in pregnancy hypertension</i>					

Julia Kaal ⁶	University of British Columbia	PhD	2016/9	2021/6	Co-supervisor
	<i>Thesis title: Care coordination among survivors of childhood, adolescent and young adult cancer: patient sharing, healthcare utilization, quality of care, and cost</i>				
Luke Spooner ^{7,8,9}	University of British Columbia	MSc	2015/9	2017/8	Supervisor
	<i>Thesis title: Preventing rheumatoid arthritis: understanding factors that influence decisions to take preventative treatments for rheumatoid arthritis</i>				
Sean Gavan	University of Manchester (UK)	PhD	2013/9	2017/7	Co-supervisor
	<i>Thesis title: An economic evaluation of a biomarker test to stratify treatment for rheumatoid arthritis</i>				
Rachel Meacock ¹⁰	University of Manchester (UK)	PhD	2012/9	2017/8	Co-supervisor
	<i>Thesis title: Economic evaluation of changes to the organisation and delivery of health services: methods and applications</i>				
Alexander Turner	University of Manchester (UK)	PhD	2013/9	2016/12	Co-supervisor
	<i>Thesis title: An economic analysis of the causes and consequences of social and emotional well-being in childhood</i>				
Wendy Gidman	University of Birmingham (UK)	MSc	2013/9	2014/9	Co-supervisor
	<i>Thesis title: Cost of illness of surgical wounds and cost-effectiveness of negative pressure wound therapy</i>				
Eleanor Heather	University of Sheffield (UK)	MSc	2011/9	2013/9	Co-supervisor
	<i>Thesis title: Cost effectiveness analysis of pharmacological interventions in paediatric rheumatology</i>				

¹ 2023-2026 Canadian Institutes of Health Research (CIHR) Doctoral Research Award: Canada Graduate Scholarships (C-GSD)

² 2021-22 PhD Salary Award from the Arthritis Society entitled "Assessing equity considerations in the care of patients with inflammatory arthritis (ACCESS)"

³ 2023-2026 Canadian Institutes of Health Research (CIHR) Doctoral Research Award: Canada Graduate Scholarships (C-GSD) entitled "Assessing equity considerations in the research and care of patients with inflammatory arthritis (ACCESS)"

⁴ 2021 NSERC Canada Graduate Scholarship – Master’s program (C-GSM) entitled "Evaluating the impact of the 'Biosimilars Initiative' for rheumatic conditions in British Columbia"

⁵ 2018 Faculty of Pharmaceutical Sciences Graduate Student & Postdoctoral Fellow Research Symposium – 1st prize oral abstract presentations. Pharmaceutical Sciences, 2018 Three Minute Thesis (3MT) – 3rd place.

⁶ Awarded 2021 CIHR Health System Impact Fellowship as a post-doctoral researcher

⁷ 2016-17 Santosh M. Wasan Graduate Student Travel Award in Pharmaceutical Sciences

⁸ Sun Life Global Investments LiveBright Scholarship Program Award

⁹ 2016 ImpactBC Scholarship in Health Care Research and Development

¹⁰ Outstanding Impact Award, Doctoral Academy, Faculty of Biology, Medicine & Health, University of Manchester

Graduated Student: Current Positions:

1. Alison McClean MSc – Research Assistant, BC Centre for Excellence in HIV/AIDS
2. Rebecca Metcalfe – Senior Scientist & Research Methodologist (Decision Science and Patient-Centred Care), Core Clinical Sciences; Julia Kaal PhD – CIHR Health System Impact Fellow, Dalhousie University
3. Julia Kaal PhD – Assistant Professor/CIHR Health System Impact Fellow, Dalhousie University
4. Ross Duncan MSc – Learning Health Systems Data Analyst, Michael Smith Health Research/BC Emergency Medicine Network
5. Luke Spooner MSc – Senior Project Manager – Pharmaceutical Management, Government of the Northwest Territories
6. Sean Gavan PhD – Senior Lecturer in Health Economics, Manchester Centre for Health Economics, University of Manchester UK
7. Rachel Meacock PhD - Senior Lecturer in Health Economics, Manchester Centre for Health Economics, University of Manchester UK
8. Alexander Turner PhD – Research Fellow in Health Economics, Manchester Centre for Health Economics, University of Manchester UK
9. Wendy Gidman MSc – Senior Consultant at PRMA Consulting Ltd, Health Economics and Outcomes Research, Cheshire, UK
10. Eleanor Heather MSc - Senior Behavioural Strategist at Ogilvy Change, London, UK

Graduate Student Supervisory Committees

Total 12: 2 current, 10 complete

PhD: Total 2: 0 current, 2 complete

MSc: Total 10: 2 current, 8 complete

Student Name	University	Program Type	Year		Supervisory Role
			Start	Finish	
Aashiq Ahamed Shukkoor	University of British Columbia	MSc	2023/9	Active	Committee member
Vienna Cheng	University of British Columbia	MSc	2022/9	Active	Committee member
Ahmad Sherbini	University of Manchester (UK)	PhD	2021/10	2022/6	Committee member*
Safa Ahmadian	University of British Columbia	MSc	2020/3	2022/6	Committee member
Shania Au	University of British Columbia	MSc	2019/1	2022/9	Committee member
Andrea Stucchi	University of British Columbia	MSc	2018/12	2021/6	Committee member
Samantha Sigurdson	Queen’s University	MSc	2018/6	2019/11	Committee member
Kate Johnson	University of British Columbia	PhD	2016/9	2020/3	Committee member
James Hicklin	University of British Columbia	MSc	2016/9	2018/4	Committee member
Harriet Ho	University of British Columbia	MSc	2016/9	2017/12	Committee member
Alyssa Howren	University of British Columbia	MSc	2016/3	2017/8	Committee member
Kirby Smith	University of British Columbia	MSc	09/2015	2017/4	Committee member

* Committee member for chapters on the impact of adverse events on health-related quality of life.

Post-doctoral Fellows Supervised

Fellow Name	Program Type	Year		Supervisory Role
		Start	Finish	
Logan Trenaman, PhD ¹	Postdoctoral Fellow, Faculty of Pharmaceutical Sciences	2020/4	2022/12	Supervisor
Magda Aguiar, PhD ^{2,3,4}	Postdoctoral Fellow, Faculty of Pharmaceutical Sciences	2018/10	2021/12	Supervisor
Alison Pearce, PhD	Visiting Postdoctoral Fellow, University of Technology (Sydney)	2018/10	2019/4	Supervisor (for 6-month visit)
Daphne Ling, PhD	Postdoctoral Fellow, Faculty of Pharmaceutical Sciences	2014/9	2016/3	Co-supervisor

1 Awarded 2020 CIHR Patient-Oriented Research Awards - Transition to Leadership Stream - Phase 1 Fellowship, ranked 3/81 in the committee.

2 Awarded 2019 CIHR Health System Impact Fellowship as a post-doctoral researcher, supported in partnership with MSFHR to study “Investing wisely: using economic modelling to optimize public health strategies to reduce harm from alcohol, tobacco and cannabis and optimize benefits in British Columbia”

3 Best poster presentation, Postdoctoral Fellow: Magda Aguiar, 2019 UBC Faculty of Pharmaceutical Sciences Graduate Student and Postdoctoral Fellow Research Symposium

4 Awarded Top Rated Abstract: Canadian Rheumatology Association Annual Scientific Meeting, Victoria, BC. February 27th 2020

Post-doctoral Fellows Supervised: Current Positions:

1. Logan Trenaman – Assistant Professor, Department of Health Systems and Population Health, University of Washington
2. Magda Aguiar - Consultant Maple Health Group
3. Alison Pearce - Stream Lead, Health Economics; Senior Lecturer, Health Economics, Faculty of Medicine and Health, University of Sydney
4. Daphne Ling – Assistant Professor (Adjunct) at Weill Cornell Medicine

Postgraduate Dissertations Supervised

Students for whom I have supervised the research component of blended taught and applied degrees, either as primary or co-supervisor.

Student Name	University	Program Type	Year		Supervisory Role
			Start	Finish	
Charlotte Desterbecq	Universite Catholique de Louvain (Belgium)	PhD	2023/10	Active	Advisor on dissertation project (literature review and discrete-choice experiment)
	<i>Thesis title: Inclusion of environmental spillovers in applied economic evaluations of healthcare products</i>				
Ellen Codling ¹	University of York (UK)	MSc	2020/5	2020/9	Co-supervisor (3-month MSc Dissertation Project placement at UBC).
	<i>Thesis title: A model-based economic evaluation estimating the long-term costs and benefits of introducing screening and brief intervention for high-risk drinking in primary care in British Columbia</i>				
Ingrid Kremer	Maastricht University (Netherlands)	MSc	2020/4	2020/8	Co-supervisor (3-month MSc Dissertation Project placement at UBC).
	<i>Thesis title: Facilitating shared decision making with a patient decision aid for choosing a treatment for multiple sclerosis</i>				
Laura Eliot ¹	University of York (UK)	MSc	2019/6	2019/9	Co-supervisor (3-month MSc Dissertation Project placement at UBC).
	<i>Thesis title: The cost-effectiveness of treatment for Idiopathic Intracranial Hypertension</i>				
Susanne Rademacher	Maastricht University (Netherlands)	MSc	2016/4	2016/8	Co-supervisor (3-month MSc Dissertation Project placement at UBC).
	<i>Thesis title: The potential cost-effectiveness of using patient decision aids to guide osteoporosis treatment</i>				
Hannah Penton	University of Sheffield (UK)	MSc	2015/7	2015/10	(3-month MSc Dissertation Project placement at UBC).
	<i>Thesis title: The routine collection of patient-reported outcome measures among patients with rheumatoid arthritis: a systematic literature review</i>				
Anna Wilding	University of Manchester	MPH	2010/9	2011/9	Supervisor (MSc Dissertation placement)
Katherine Gaudreau	London School of Hygiene & Tropical Medicine (UK)	MSc	2009/9	2010/9	Supervisor (MSc Dissertation placement)

¹ Student was awarded a 'Distinction' for their dissertation

PharmD Students Supervised

Student Name	University	Program Type	Year		Supervisory Role
			Start	Finish	
Hilary Wu	University of British Columbia	PharmD	2016/5	2016/6	Supervisor (Research rotation)

Jason Tan	University of British Columbia	PharmD	2016/5	2016/5	Supervisor (Research rotation)
Tamara Mihic	University of British Columbia	PharmD	2015/11	2015/12	Supervisor (Research rotation)
Gloria Su	University of British Columbia	PharmD	2015/5	2015/5	Supervisor (Research rotation)

Undergraduate Summer (SSRP) Students, Academic Assistants (RA) and Directed Studies Students Supervised

Student Name	Program Type	Year		Supervisory Role
		Start	Finish	
Jack Smith	PHAR485 (Research Project) (15 credits) and PHAR491 (Honours Thesis) (12 credits)	2025/1 (Registered)		Supervisor
Sarah Batke	Summer Student Research Placement	2024/5	2024/7	Supervisor
Jack Smith	Summer Student Research Placement	2024/5	2024/7	Supervisor
Ivy Liu	Volunteer (BPSc Program)	2022/10	2024/3	Supervisor
Caitlin Chew	Undergraduate Academic Assistant	2019/12	2020/9	Supervisor
Enav Zusman	PHAR414 Directed Studies in Pharmaceutics and Biopharmaceutics (3 credits)	2019/4	2019/9	Supervisor
Catherine Gai	UBC WorkLearn / Summer Student Research Placement	2019/6	2019/8	Supervisor
Joshua Quisias	Undergraduate Academic Assistant	2019/6	2019/8	Supervisor
Doris Stratoberdha	Summer Student Research Placement	2019/5	2019/8	Supervisor
Jenny Gu	Directed Studies Student (Pharmacology and Therapeutics - PCTH 448E) (6 credits)	2018/9	2019/4	Supervisor
Kathleen Lau	Undergraduate Academic Assistant	2017/11	2018/5	Supervisor
Joshua Quisias	Undergraduate Academic Assistant	2016/9	2017/1	Supervisor
Madelaine Bell	Summer Student Research Placement	2016/5	2016/7	Supervisor
Joshua Quisias	Summer Student Research Placement	2016/5	2016/9	Supervisor
Madelaine Bell*,*¥	Summer Student Research Placement	2015/6	2015/9	Supervisor
Alyssa Pompeo*	Summer Student Research Placement	2015/6	2015/9	Supervisor
Lingxi Li	Summer Student Research Placement	2015/5	2015/9	Supervisor

* Student awarded Yee Bong Pang Endowment Fund Summer Research Studentship.

† Student won 1st Place at the end-of-placement Alan C. Hayman Poster Competition.

¥ Student chosen for the 2016 Canadian Society for Pharmaceutical Sciences National Summer Student Award & Annual Conference Poster Competition

(d) Continuing Education Activities

(e) Other

Teaching on Residency Programs

Activity	Institution/Company	Class size	Dates
Neurology Academic Halfday/June 9/Neuroethics	University of British Columbia/Vancouver Coastal Health	28	2023/6
Instructor – Hospital Pharmacy Residents. (Teaching, 2 hours)	BC Interior Health/Faculty of Pharmaceutical Sciences	45	2018/8

Teaching and Development of Health Economics Workshops

During my sabbatical visit to UC Louvain, Belgium, I developed a short course (one day/seven hours) on patient-oriented discrete choice experiments (DCE). The course covered the design and analysis of DCEs and approaches to integrating patient and public involvement in these studies at all stages of the research project. It was aimed at and attended by students, academics, and policymakers across Belgium. The class size was 21.

I co-developed a new two-day introductory workshop as part of my involvement in the BC SUPPORT Unit's Health Economics and Simulation Modelling Methods Cluster aimed at researchers, decision-makers, administrators and funders of research projects and assumed prior economic knowledge.

Activity	Institution/Company	Class size	Dates
Unlock the Power of Patient-Oriented Discrete Choice Experiments - Short Course	Université catholique de Louvain (UC Louvain)	21	2023/10
Developer - Integrating Health Economics in Clinical Research (Two-Day Workshop)	BC Support Unit	27	2019/2
Instructor – Integrating Health Economics in Clinical Research (Session: Measuring and valuing health outcomes). (2 hours)	BC Support Unit	27	2019/2

9. SCHOLARLY AND PROFESSIONAL ACTIVITIES

(a) Areas of special interest and accomplishments

Summary

My program of research encompasses policy and service evaluation, using choice-based experiments to understand patient-physician decision-making and design clinical studies, and measurement and valuation of health outcomes. Since joining UBC in 2014, I have received >\$1.8m of competitive, peer-reviewed funding as Principal Investigator (\$850,000 from CIHR), a Fulbright Canada and UC Louvain (Belgium) Visiting Researcher awards to support my sabbatical, two salary awards (incl. Michael Smith Health Research BC Scholar Award) totalling \$630,000. I am co-investigator on grants totalling over \$4m (>\$12m through my career), including the NIH (\$704,575), and team grants totalling almost \$20m. I publish in leading medical and policy journals, including first-authored BMJ and Health Economics papers. I have given 41 invited presentations (20 international) in Europe, North America and Africa, and over 100 conference abstracts. In 2016, I received the Association of Faculties of Pharmacy of Canada New Investigator Research Award.

(b) Research or equivalent grants (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC))

48 Grants, Total \$33,520,508

	Career	Since 2014 (UBC)
Principal Investigator:	\$1,893,651	\$1,841,155 [†]
<i>Operating grants</i>		\$1,211,555
<i>Salary Awards</i>		\$630,000
Co-applicant	\$12,280,583	\$4,037,543 ^{††}
Team / foundation grants (as Co-I)	\$19,346,274	\$2,250,000
Total	\$33,520,508	\$8,129,098

[†]\$878,052 and ^{††}\$1,852,016 from CIHR; 15 CIHR in total (7 as PI)

Granting Agency	Subject	COMP	\$ Total	Year	Principal Investigator	Co-Investigator(s)
Michael Smith Health Research BC	Estimating the economic impacts of extreme weather events on healthcare systems: A qualitative inquiry to inform the development of an evaluation framework.	C	\$19,016	2024 - 2025	Dr M. Harrison	G. Apanataku N. Esfandiari C. Mitton M. Sutton
CIHR	Applying an equity and intersectionality lens to understanding the burden of arthritis on aging Canadians (APPROACH)	C	\$69,094	2024 - 2025	Dr M. De Vera	Dr. M. Harrison Ms. M. Thomas Dr. J. Avina-Zubieta Dr. C. Barnabe Ms. N. Gheshlaghi Mx. P. Kang

BC Ministry of Health	Bridging the gap between expanded pharmacist services and payment models	C	\$250,000	2023 - 2024	Dr. W. Zhang	Dr. O. Tseng Dr. N. Bansback Dr. M. Harrison Dr. M. Law Dr. L. Lynd Dr. C. Mitton Dr. P. Zed
CIHR	Re-engineering health policy decision-making for equitable allocation of resources	C	\$575,000	2023 - 2027	Dr. S. Ali Dr. B.H. Sander Ms. K.M. Lee	Dr. M. Asaria Dr. Y. Bombard Dr. K. Chan Prof. R. Cookson Dr. M. Harrison Dr. J. Hopkins Mr. N. Iragorri Dr. Z. Li Dr. S. Mishra Prof. L. Prosser Mr. M. Saini Dr. S. Shoush Dr. E. Spackman Mr. D. Steele Ms. M. Yeung
CIHR	Re-purposing the Ordering of 'Routine' laboratory Tests among hospitalized medical patients (RePORT study)	C	\$665,552	2022 - 2026	Dr. A. Ambasta Dr. I. Ma Dr. H.T. Stelfox Dr. J.M. Holroyd-Leduc Dr. A. Wei-Yeh Shih	Dr. M. Harrison Dr. D. McCaughey Dr. C. Shukalek Dr. J. Lockyer Dr. C. Naugler Dr. T. Williamson Dr. B. Manns Dr. M. Parilla Lopez Mrs. P. Mathura Mrs. S. Zelinsky Dr. M. Chen
CIHR	Exploring health vulnerabilities to climate change: a participatory approach to research design	C	\$19,939	2022 - 2023	Dr. M. Harrison Ms. G. Apantaku	Dr. T. Satterfield
CIHR	Towards addressing equity considerations in research and care of patients with inflammatory arthritis (ACCESS)	C	\$19,870	2022 - 2023	Ms. M. Thomas	Dr. M. Harrison Dr. M. De Vera
CIHR	Patient Treatment Preferences and Decisional Needs for Heart Failure Medications	C	\$100,000	2022 - 2023	Dr. R. Turgeon Dr. M. Harrison	Dr. N. Bansback Dr. J. Code Dr. M. De Vera Dr. B. Snow Dr. S. Virani

CIHR	Options for Increasing Plasma Supply in Canada: A Health Economic Preference and Modelling Study (HEMO-CAN)	C	\$322,500	2021 - 2024	Dr. N. Bansback	Dr. M. Harrison Dr. R. Grieve Dr. K. Holloway Dr. D. Devine Dr. S. Shechter Dr. J. Cairns
Vancouver Coastal Research Institute	Community-based antibiotic therapy for persons with severe bacterial infections and substance use disorders in a low-barrier, home-like, skilled nursing facility: an evaluation of the CTCT model of care	C	\$30,000	2021 - 2022	Dr. J. Hajek Dr. A. Palepu	Dr. M. Harrison Dr. W. Connors Dr. H. Daumann Dr. R. Joe Dr. T. Oravec Dr. V. Weaver
CIHR	Evaluating the impact of a mandatory switching policy for biosimilars	C	\$298,350 (\$99,450)	2021 - 2024	Dr. M. Harrison Dr. N. Bansback	Dr. M. Law Dr. M. De Vera Dr. R. Beall Dr. F. Clement Dr. A. Anis
CIHR	Re-Purposing the Ordering of 'Routine' laboratory Tests on clinical teaching units (RePORT study)	C	\$100,000	2021 - 2022	Dr. A. Ambasta Dr. I. Ma Dr. H.T. Stelfox Dr. J.M. Holroyd-Leduc Dr. A. Wei-Yeh Shih	Dr. M. Harrison Dr. D. McCaughey Dr. C. Shukalek Dr. J. Lockyer Dr. C. Naugler Dr. T. Williamson Dr. B. Manns Dr. M. Parilla Lopez
Michael Smith Foundation for Health Research	Priorities for Rural and Remote Health Resource allocation in Northern BC (PLURAL North)	C	\$13,500	2021 - 2022	Dr. M. Harrison Dr. T. Healy	Dr. M. Aguiar Ms. G. Apantaku Ms. L. Frederick Dr. K. Jong
EuroQol Foundation	Can adding routinely collected EQ-5D-5L administrative data improve predictions about who will be a high-cost users of healthcare?	C	\$35,000 €23,360	2020 - 2021	Dr. S. Bryan Dr. L. Trenaman	Dr. M. Harrison Dr. N. Bansback Dr. K. McGrail Dr. R. Sawatzky
Canadian Initiative for Outcomes in Rheumatology cAre (CIORA)	Health Economic Evaluation of the Mandatory Switching Policy for Biosimilars in Patients with Rheumatoid Arthritis	C	\$98,984	2020 - 2022	Dr. N. Bansback	Dr. M. Harrison Dr. M. Law Dr. J. Kur Dr. M De Vera Dr. A. Anis
CIHR	In the shadows of the opioid crisis: the epidemiology and impact of methamphetamine use in Canada	C	\$100,000	2020 - 2021	Dr. J Cragg	Dr. P. Bach Dr. L. Lynd Dr. M. Harrison Dr. L. Liu

BC Support Unit (CIHR)	You talk, we listen: advancing health economics methods for rural and remote health research by gathering local communities' knowledge and experiences in health care decision making	NC	\$63,816	2020 - 2021	Dr. M. Harrison Dr. M. Aguiar	Dr. T. Healy Mr. J. Kim Ms. L. Frederick
BC Support Unit (CIHR)	Advancing the methods for using routinely collected PROMs, PREMs and administrative data for health economics research	NC	\$67,000	2020	Dr. M. Harrison Dr. L. Trenaman	Dr. K. McGrail Dr. E. Karim
Canadian Initiative for Outcomes in Rheumatology cAre (CIORA)	Perspectives on the implementation of a multidisciplinary conference fee code for community-based patients with rheumatic disease in BC (RHEUM-NURSE)	C	\$66,665	2019 - 2020	Dr. M. Harrison	Dr. M. Teo Dr. K. Shojania Dr. M. De Vera Ms. C. Koehn Dr. J. Kur Ms. P. Patrick Dr. M. Aguiar
National Institutes of Health (NIH)	Informing Choice for Neurotechnological Innovation in Pediatric Epilepsy Surgery	C	\$704,575 US\$542,216	2018 - 2021	Dr J. Illes Dr P. McDonald	Dr. M. Harrison Dr. Hader Dr. Ibrahim Dr. Weil
Genome British Columbia (Genome BC)	Quantifying the value of genomics-driven healthcare for children with rare diseases: a multi-country economic analysis	C	\$500,000	2018 - 2020	Dr. D. Regier Dr. B. Schroeder	Dr. J. Buchanan Dr. S. Wordsworth Dr. N. Dragojlovic Dr. L. Lynd Dr. J. Friedman Dr. C. van Karnebeek Dr. A. Elliott Dr. M. Harrison
BC Support Unit (CIHR)	Using Health Economic Methods to Design Patient-Oriented Clinical Studies	NC	\$57,550	2018 - 2019	Dr. M. Harrison Dr. T. Laba	Dr. M Hudson Dr. B. Thomb Ms. T Burch
Pfizer Canada	Perspectives on multidisciplinary care for patients with rheumatic disease in BC	NC	\$50,000	2018 - 2019	Dr. M. Harrison Dr. M. Teo	
Michael Smith Foundation for Health Research (Scholar Award: Salary Award)	Incentivizing the delivery of sustainable care of chronic diseases in Canada: Case studies in musculoskeletal disease	C	\$450,000	2017 - 2022	Dr. M. Harrison	

Canadian Centre for Applied Research in Cancer Control	Communicating imprecision in prognostic tools	C	\$28,598	2016 - 2017	Dr N. Bansback	Dr. M Harrison Dr. P. Han Dr. B. Rabin Dr. S. Peacock
CIHR	A population-based analysis of multi-disciplinary rheumatology nursing care for people with complex rheumatic diseases.	C	\$271,397	2016 - 2019	Dr. M. Harrison	Dr. K. Shojania Dr. M. Law Dr. K. McGrail Dr. M. De Vera Dr. R. Sawatzky Ms. C. Koehn Dr. J. Kur Ms. H. Davidson
The Arthritis Society	A population-based analysis of multi-disciplinary rheumatology nursing care for people with complex musculoskeletal disorders.	C	\$74,776 (Approved for \$346,173, reverted to top-up funding alongside CIHR award)	2016 - 2019	Dr. M. Harrison	Dr. K. Shojania Dr. M. Law Dr. K. McGrail Dr. M. De Vera Dr. R. Sawatzky Dr. J.A. Avina-Zubieta Ms. C. Koehn Dr. J. Kur Ms. H. Davidson
The Arthritis Society (Salary Award)	Incentivizing the delivery of sustainable health care in Canada; applications in musculoskeletal Disease	C	\$180,000	2016 - 2019	Dr. M. Harrison	Dr. K. Shojania Dr. M. Law Dr. K. McGrail Dr. M. De Vera Dr. R. Sawatzky Dr. J.A. Avina-Zubieta Ms. C. Koehn Dr. J. Kur Ms. H. Davidson
Institute for Health Transformation and Sustainability	Unlocking the Potential of Patient-Reported Outcome Measures (PROMs) to Support Health Care System Sustainability: Scoping Phase	NC	\$26,613	2016 - 2017	Dr. M. Harrison	Dr. S. Bryan Dr. N. Bansback
CIHR	Improving Access to Medicines in Canada and Abroad	C	\$2,250,000 (\$375,000)	2016 - 2022	Dr M. Law	Dr. N. Bansback Dr. L. Goldsmith Dr. M. Harrison Dr. A. Holbrook Dr. S. Majmudar Dr. M. Mamdani Dr S. Wong
Canadian Initiative for Outcomes in Rheumatology cAre (CIORA)	Preventing rheumatoid arthritis (Pre-RA): perspectives of people at risk and of rheumatologists on selected interventions	C	\$82,933	2015 - 2017	Dr. M. Harrison Dr. M. Hudson	Dr. N. Bansback Mrs. C. Koehn

Kidney Foundation of Canada	Assessing preferences for subsequent entry biologics of erythropoiesis stimulating agents for treatment of anemia in chronic kidney disease: A discrete choice experiment	C	\$98,806	2015 - 2018	Dr. C. Lo	Dr. G. Da Roza Ms. N. Tsao Dr. M. Harrison Dr. M. Leung Dr. J. Marin Dr. D. Martinsun
Canadian Institute for Health Information	The Impact of Pharmacist Medication Review Services in British Columbia	C	\$50,000	2015 - 2016	Dr. M. Law	Dr. M. Harrison Ms. Y. Cheng Ms. J. Kratzer
BC PMI / PHEMI / Merck	Diabetes interdisciplinary Research on Epidemiology, Costs, and treatment (DIRECT)	NC	\$298,564	2015 - 2018	Dr. L. Lynd	Dr. M. Harrison Dr. A. Anis
Medical Research Council (UK)	Maximizing the Therapeutic Potential by Application of Novel and Stratified approaches (MASTERPLANS)	C	\$17,096,274 ⁺	2015 - 2019	Dr. I. Bruce	Dr. M. Harrison 26 others
Michael Smith Foundation for Health Research	Analysis of Accelerated Integrated Primary and Community Care (aIPCC) Data	C	\$100,000	2014 - 2015	Dr. K. McGrail	Dr. M. Law Dr. M. McGregor Dr. S. Berg Dr. C. Mitton Dr. S. Wong Dr. S. Bryan Dr. M. Harrison
Technology Stratification Board (UK)	The economics of stratified medicine in rheumatoid arthritis	C	\$189,663 ⁺	2014 - 2015	Dr. K. Payne	Dr. M. Harrison Dr. A. Barton
National Institute for Health Research (NIHR) (UK)	Cost of illness of open surgical wounds and cost-effectiveness of negative pressure wound therapy for the treatment of severe pressure ulcers	C	\$167,400 ⁺	2014 - 2016	Dr. N. Cullum	Dr. M. Harrison
National Institute for Health Research (NIHR) (UK)	Stroke reduction via improved opportunistic screening for atrial fibrillation. An evaluation of the clinical and economic benefits of the RapidRhythm device within primary care	C	\$1,572,667 ⁺	2014 - 2016	Dr. J. Corden	Dr. M. Harrison Dr. M. Sutton Dr. D. Reeves
National Institute for Health Research (NIHR) (UK)	Culturally-adapted family intervention (CaFI) for African Caribbeans with schizophrenia and their families: A feasibility study of implementation and acceptability	C	\$635,711 ⁺	2014 - 2017	Dr. D. Edge	Dr. M. Harrison Miss R. Meacock Miss. K Forsyth

National Institute for Health Research (NIHR) (UK)	Cost effectiveness analysis of pharmacological interventions in paediatric rheumatology	C	\$167,400 ⁺	2013 – 2015	Dr. D. Symmons	Dr. M. Harrison
National Institute for Health Research (NIHR) (UK)	A pilot randomized controlled trial comparing patient-reported and clinical outcomes in edentulous patients with standard implant-retained overdentures and mini-implant-retained overdentures in heavily resorbed mandibular ridges	C	\$433,285 ⁺	2013 – 2015	Dr. C. Barclay	Dr. M. Tickle Dr. M. Harrison Dr. T. Walsh Dr. S. Jawad
Central Manchester Foundation Healthcare Trust	Haemophilia health economics: Immune Tolerance Study	NC	\$52,096 ⁺	2012 – 2013	Dr. M. Harrison	-
National Institute for Health Research (NIHR) (UK)	The effectiveness of the Older prisoner Health and Social Care Assessment and Plan (OHSCAP): A Randomised Controlled Trial	C	\$946,710 ⁺	2012 - 2015	Dr. K. Forsyth	Dr. M. Harrison Dr. J. Senior Dr. K. O'Hara Dr. D. Challis Miss R. Meacock Dr. D. Edge Dr. J. Shaw Dr. R. Webb
National Institute for Health Research (NIHR) (UK)	Developing, testing and implementing the NSPCR Patient Safety Toolkit in general practices in England	C	\$1,079,532 ⁺	2012 – 2015	Dr. A. Avery	Dr. M. Harrison Dr. U. Kadam Dr. J.M. Valderas Dr. S. Campbell Dr. S Slight Dr. S. Rodgers Dr. A. Sheikh
National Institute for Health Research (NIHR) (UK)	Evaluating the efficacy of the Promoting Alternative Thinking Strategies (PATHS) curriculum in promoting social and emotional wellbeing among children in primary school: a cluster randomized controlled trial	C	\$2,251,544 ⁺	2012 – 2017	Dr. N. Humphrey	Dr. M. Harrison Dr. A. Lendrum Dr. M. Wigglesworth Dr. C. Joyce Dr. L. Wo Dr. R. Calam Dr. G. Squires Dr. K. Woods
Medical Research Council (UK)	Attribution of patient reported outcomes to the effects of care providers	C	\$759,769 ⁺	2010 - 2014	Dr. M. Sutton	Dr. M. Harrison Dr. G Dunn Ms. K Major Dr. D. Symmons

Manchester Academic Health Sciences Centre	The health economic impact of implementing flexiscope screening of the large bowel across Manchester	C	39,359 ⁺	2010	Dr. M. Sutton	Dr. M. Harrison
--	--	---	---------------------	------	---------------	------------------------

⁺GBP conversions made using rate of CAD\$1.8 = GBP £1

As official collaborator

Granting Agency	Subject	COMP	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
Agency for Healthcare Research and Quality (AHRQ)	A Patient Perspective on Value: Medicare's Hospital Value-based Purchasing Program	C	US\$99,437	2020 - 2021	Dr J Hoch Dr. L Trenaman	None
Health Research Board (Ireland)	Oral flucloxacillin alone versus flucloxacillin and phenoxymethylpenicillin for the emergency department outpatient treatment of cellulitis: a non-inferiority randomised controlled trial.	C	\$1,130,354 ⁺ (\$367,785)	2015 - 2018	Dr. A. Wakai	Dr. B. Gannon Dr. F. Boland Dr. K. Laupland Dr. C. Deasy Dr. F. Fitzpatrick
<p><i>Official role: "Dr. Harrison will be a member of the project's Scientific Advisory Group (SAG). Dr. Harrison has already made a critical and substantive contribution towards the study design of the pharmacoeconomic analysis and health-related quality of life (HRQL) assessment work package detailed in the grant application. Dr. Harrison will provide expert informal peer review regarding the execution of the health economics work package of the planned research. He will also provide informal peer review regarding the critical interpretation of the study data and results of the pharmacoeconomic analysis and health-related quality of life (HRQL) assessment work package."</i></p>						

⁺Euro conversions made using the rate of CAD\$1.42 = Euro1

(c) Research or equivalent contracts (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC)).

Granting Agency	Subject	COMP	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
UBC Faculty of Pharmaceutical Sciences: SoTL Research Stream Mini-Grant Program	Improving the Quality and Variety of My Teaching Practice Through Technology	C	\$990 (\$990)	2015	Dr. M. Harrison	

(d) Invited Presentations**International**

1. **Harrison M.** The road to increased biosimilar market share in British Columbia, Canada: Navigating the switchbacks. University of Manchester. Manchester Centre for Health Economics (MCHE) Seminar. 4th December 2023.
2. **Harrison M.** The road to increased biosimilar market share in British Columbia, Canada: Navigating the switchbacks. Université catholique de Louvain (UC Louvain), Institute of Health and society (IRSS) Seminar Series. Faculty of Public Health. Belgium. 11th October 2023.
3. **Harrison M.** British Columbia Ministry of Health: Health Technology Assessment Committee Environmental Considerations. Ministères belges de la Santé, du Climat, de l'Environnement, du Développement durable et du Green Deal (Belgian Ministries of Health, Climate, Environment, Sustainable Development and Green Deal). Brussels. Belgium. 29th September 2023.
4. **Harrison M.** Ethical Considerations for Discrete Choice Experiments with Caregivers. CITI Program Webinars, Fort Lauderdale, FL. USA. 29th March 2023.
5. **Harrison M.** Equity in the Health Technology Assessment Process. University of California (Davis) Public Health Sciences Seminar Series. USA. 17th March 2023.
6. **Harrison M.** Commercialization – Moving from rare to common: Patient and physician decision-making. Precision Medicine World Conference in Silicon Valley, San Jose, CA. USA. 25th January 2023.
7. **Harrison M.** Through a Northern Lens: Using Arts-Based Methods to Reveal Community Perspectives on Health and Wellbeing. Health organisation, policy and economics (HOPE). University of Manchester UK. 8th August 2022.
8. **Harrison M.** Co-producing randomized clinical trials with patients: a hypothetical case study in scleroderma. University of California (Davis) Center for Healthcare Policy and Research / Division of Health Policy and Management (EPI 291) Seminar Series (2021/22). 9th February 2022.
9. **Harrison M.** Yale Rheumatology Symposium: State-of-Art Rheumatology Symposium and Workshop (virtual meeting). Understanding the Preferences of Potential Recipients and Physicians for Treatments to Prevent Clinical Arthritis. 19th May 2021.
10. **Harrison M.** A role for health economics methods in designing patient-oriented research? Stem cell transplant in scleroderma. The Centre for Health Economics Research and Evaluation (CHERE), University of Technology Sydney, Australia. 11th December 2019
11. **Harrison M.** A role for health economics in the design of patient-oriented research studies? Case studies in rheumatic disease. Health Economics Unit, University of Birmingham, UK. 19th March 2019
12. **Harrison M.** Preventing Rheumatoid Arthritis (Pre-RA): Preferences of Potential Recipients & Health Care Professionals for Preventative Treatment. University of California San Francisco, USA. 15th March 2018.
13. **Harrison M.** Preventive treatment for rheumatoid arthritis: are we looking in the right direction? Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. 12th January 2018.
14. **Harrison M.** Has the UK Quality and Outcomes Framework improved outcomes for people with chronic diseases? Lessons for other health care systems. *Knowledge Exchange Forum. School of Public Health, University of Rwanda.* October 19th, 2016.
15. **Harrison M.** Sustainability in health care: Looking for answers within. *Faculty of Pharmaceutical Sciences Special Seminar, Vancouver, BC.* December 2013.
16. **Harrison M.** Does waiting time influence the effectiveness of surgery? Lessons from the NHS PROMS Project in the UK. *Centre for Clinical Epidemiology and Evaluation Rounds, Vancouver General Hospital, Vancouver, BC,* June 2013.
17. **Harrison M.** Vienna Healthcare Lectures¹: The NHS Patient Reported Outcome Measure Project. *Gesundheitsförderung und Prävention, Vienna, Austria,* May 21, 2012.
18. **Harrison M.** Vienna Healthcare Lectures: The role of the National Institute for Health and Care Excellence (NICE). *Gesundheitsförderung und Prävention, Vienna, Austria,* May 22, 2012.

¹ The Vienna Healthcare Lectures are 90-minute talks and group discussions given by invited speakers from European health care systems during a 3-day course.

19. **Harrison M** & Boonen A. Valuing Health; Measuring outcomes in rheumatoid arthritis. *OMERACT Working Group Meeting, Kota Kinabalu, Malaysia, May 2010.*
20. Harrison M. Towards a reference approach to derive QALYs for economic evaluations in rheumatology. *OMERACT (Outcome Measures in Rheumatology) Group, University of Toronto, Canada, May 2008.*

National

1. **Harrison M.** Benchmarking with BC: Analyzing How the Biosimilars Switch Policy has Impacted Drug Spending and Health Outcomes *The Canadian Institute's Pathways to Access & Reimbursement Forum, Toronto ON.* January 2023 [Invited]
2. Bansback N, **Harrison M**, Metcalfe R. How to design clinical trials to increase enrollment and impact: Patient-oriented approaches to trial design. *Work in Progress Seminar Series, St. Paul's Hospital, Vancouver, BC,* April 13th, 2022.
3. **Harrison M**, Apantaku G, Healy T, Grogan J. PLURAL: "You talk, we listen" Advancing health economics methods for rural and remote health research by gathering local communities' knowledge and experiences in health care decision making. Research Week, University of Northern British Columbia. March 2nd 2021
4. **Harrison M** & Bansback N. Co-designing Clinical Trials with Patients. The BC AHSN Patient Engagement in Clinical Trials Community of Practice. National online presentation via Zoom. February 9th, 2021.
5. **Harrison M.** A role for health economics methods in designing patient-oriented research? Stem cell transplant in scleroderma. BC Support Unit Health Economics and Simulation Modelling Half Day, Vancouver, February 16, 2020.
6. **Harrison M** & Burch T. Scleroderma Association of British Columbia. Identifying patient preferences when considering stem cell transplant as a treatment option for Scleroderma. Annual General Meeting and Conference. October 5th, 2019 (<https://youtu.be/4OAtqLApQ4g>)
7. **Harrison M.** Health economics for patient-oriented research: case studies in rheumatology. Presentation to the Arthritis Research Canada Board, Canada. 25th June 2019.
8. **Harrison M.** What matters to people with scleroderma when considering a new treatment such as stem cell transplant? Montreal Scleroderma Stem Cell Meeting, Montreal, Canada. 12th April 2018.
9. **Harrison M.** Preventing arthritis: would you if you could? *Reaching Out with Arthritis Research (ROAR) 2018 (an annual public forum and live webcast presented by the Arthritis Patient Advisory Board to bridge the gap between arthritis research and the public).* 29th September 2018. <https://www.arthritisresearch.ca/roar-2018-mark-harrison/>
10. **Harrison M.** What are the impacts of billing codes for nurse management of complex rheumatic diseases in British Columbia? Let's talk about it... *Knowledge Exchange, British Columbia Ministry of Health, Victoria, BC.* 27th July 2017.
11. **Harrison M.** Using Routinely Collected Data to Explore the Impact of Changes in Health Care Policy. *Faculty of Pharmaceutical Sciences Seminar Series.* March 29th, 2017.
12. **Harrison M.** Care of people with complex rheumatic diseases. *Arthritis Patients Advisory Board. Arthritis Research Centre of Canada, Richmond, BC.* November 8th, 2016.
13. **Harrison M.** Incentivized care for chronic diseases. *Arthritis Research Centre of Canada Research Retreat.* June 18, 2015.
14. **Harrison M.** Were emergency admissions for ambulatory care sensitive conditions reduced by the UK pay for performance scheme? *Centre for Clinical Epidemiology and Evaluation (C2E2) Rounds, Vancouver Coastal Health Research Institute, Vancouver, BC.* June 22, 2015.
15. **Harrison M.** The Sustainable Health Care Initiative. *Providence Health Care, Day in the Life Series. St. Paul's Hospital, Vancouver, BC,* May 28, 2015.
16. **Harrison M.** Sustainable Health Care – Looking for the Answers Within the System. *Rx&D Innovation and Healthcare Sustainability Policy Forum, Vancouver, BC,* January 26, 2015.
17. **Harrison M.** Initiative for Sustainable Health Care Launch. *University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC,* January 21, 2015.
18. **Harrison M.** Primary care pay-for-performance in England. Were emergency admissions for ambulatory care sensitive conditions reduced? *UBC School of Population and Public Health, Vancouver, BC,* October 9, 2014.
19. **Harrison M.** Sustainability in health care: Looking for answers within. *Work in Progress Seminar Series, St. Paul's Hospital, Vancouver, BC,* September 10, 2014.

20. **Harrison M** & Dusheiko M. Does better management of chronic conditions in general practice reduce emergency hospital admissions? *Department of Health, Leeds, UK*, July 2011.
21. Harrison M. The use of patient-reported outcome measures in rheumatological conditions. *National Primary Care Research and Development Centre Rounds, University of Manchester, UK*, July 2010.

(e) Other Presentations

Media Interviews

Television

- 2020/3 **Arthritis Network:** Interview: Scleroderma and health economics. #CRArthritis Interview at the Arthritis Broadcast Network Booth. 4th March 2020. The event informed and educated over 1 million people on Twitter and 6,500 on Facebook over the 4-day conference. Arthritis Broadcast Network is a multi-media platform for the arthritis community to share news, information and stories about living with arthritis.
<https://www.youtube.com/watch?v=iguqEiYxle0>
- 2019/2 **Arthritis Network:** Interview: Pharmaceutical Sciences and Health Economics. #CRArthritis Interview at the Arthritis Broadcast Network Booth. 28th February 2019
"Arthritis Broadcast Network's #CRArthritis Facebook and Twitter live event uses the latest social media technology, consumer-patient "reporters" from Arthritis Consumer Experts, in collaboration with the Arthritis Patient Advisory Board of Arthritis Research Canada, Canadian Arthritis Patient Alliance, and Canadian Spondylitis Association groups to bring live interviews with rheumatology experts into the laptops and cellphones of people living with arthritis from coast-to-coast." These interviews reached >365,000 people on Twitter and 11,568 people on Facebook. <https://youtu.be/v-SFXBpgzss>
- 2018/6 **UBC Pharm Sci Communications Research in Focus:** Examining Signals in the Data with Dr. Mark Harrison. <http://stories.pharmsci.ubc.ca/health-outcomes-research-mark-harrison>
Featured in: **UBC Today** June 26th, 2018:
<https://secure.campaigner.com/csb/Public/show/cgvq-q5pib--h5v47-8i0ceur3>
- 2018/2 **Arthritis Network:** Interview: Research in Focus: Patient-oriented program of research. #CRArthritis Interview at the Arthritis Broadcast Network Booth. 22nd February 2018.
"Arthritis Broadcast Network's #CRArthritis Facebook and Twitter live event uses the latest social media technology, consumer-patient "reporters" from Arthritis Consumer Experts, in collaboration with the Arthritis Patient Advisory Board of Arthritis Research Canada, Canadian Arthritis Patient Alliance, and Canadian Spondylitis Association groups to bring live interviews with rheumatology experts into the laptops and cellphones of people living with arthritis from coast-to-coast." These interviews reached >45,000 people across Canada. <https://www.pscp.tv/w/1jMKgqzANMjJL>
- 2015/1 **City TV, British Columbia:** Interview: The Sustainable Health Care Initiative (University of British Columbia/Faculty of Pharmaceutical Science). 21st January 2015.
<https://www.youtube.com/watch?v=ewQTccPtVHg>

Radio

- 2015/1 **Canadian Broadcasting Corporation (CBC):** British Columbia, On the Coast, Interview: The Sustainable Health Care Initiative (University of British Columbia/Faculty of Pharmaceutical Science). 21st January 2015.
- 2015/1 **KRPI 1550AM Bellingham, USA:** Interview: The Sustainable Health Care Initiative (University of British Columbia/Faculty of Pharmaceutical Science). 20th January 2015.

Blog

- 2022/3 **CHEOS Research in Action. Sean Sinden.** Clinical trials are the gold standard for informing clinical practice. How can decision sciences improve their real-world impacts? 25th March 2022. <https://www.cheos.ubc.ca/research-in-action/clinical-trials-are-the-gold-standard-for-informing-clinical-practice-how-can-decision-sciences-improve-their-real-world-impacts/>

(f) Other

Workshops Presented

1. **Harrison M.** Arthritis Research Canada Training Day: Peer Review Panel. *Arthritis Research Canada, Vancouver, Canada.* 1st May 2024.
2. **Harrison M.** North West Research for Patient Benefit Workshops: The role of the Research Design Service and Grantspersonship. *National Institute for Health Research Research Design Service, Greater Manchester, UK.* 2010.
3. **Harrison M.** North West Research for Patient Benefit Workshops: Developing Health Economics Components of Research Grants. *National Institute for Health Research Research Design Service, Greater Manchester, UK.* 2010.
4. **Harrison M.** North West Research for Patient Benefit Workshops: The role of the Research Design Service and Grantspersonship. *National Institute for Health Research Research Design Service, Greater Manchester, UK.* 2011.
5. **Harrison M.** North West Research for Patient Benefit Workshops: Developing Health Economics Components of Research Grants. *National Institute for Health Research Research Design Service, Greater Manchester, UK.* 2011.
6. **Harrison M.** North West Research for Patient Benefit Workshops: The role of the Research Design Service and Grantspersonship. *National Institute for Health Research Research Design Service, Greater Manchester, UK.* 2012.
7. **Harrison M.** North West Research for Patient Benefit Workshops: Developing Health Economics Components of Research Grants. *National Institute for Health Research Research Design Service, Greater Manchester, UK.* 2012.
8. **Harrison M.** North West Research for Patient Benefit Workshops: The role of the Research Design Service and Grantspersonship. *National Institute for Health Research Research Design Service, Greater Manchester, UK.* 2013.
9. **Harrison M.** North West Research for Patient Benefit Workshops: Developing Health Economics Components of Research Grants. *National Institute for Health Research Research Design Service, Greater Manchester, UK.* 2013.

(g) Conference Participation (Organizer, Keynote Speaker, etc.)

Organizer

Key: * Organizer and lead applicant
Underlined: Co-applicants

1. Law M, **Harrison M**, Palmer K. CHSPR Conference 2020: Private Parts. Co-organizer of 2020 conference, Vancouver, March 2020.
2. **Harrison M***, Sadatsafavi M, Bryan S, Koehn C. The contribution of PROMs to healthcare sustainability in the pharmaceutical setting. *Panel: Canadian Society of Pharmaceutical Sciences Conference. Richmond, BC,* June 2016.
3. **Harrison M***, Bansback N, Bryan S, Marshall D. Organizer and lead applicant: The contribution of PROMs to health care sustainability. *Panel: 2016 CADTH Symposium. Ottawa,* April 2016.

4. **Harrison M, Bryan S*, Karnon J, Scotland G.** Breaking the Addiction to Adoption in Health Economics: Perspectives from Australia, Scotland, Canada and England. *Panel: International Health Economics Association (iHEA) conference, Sydney, July 2013*
5. **Harrison M***, Boonen A. OMERACT Quality-Adjusted Life Years (QALY) *Special Interest Group session: OMERACT Patient Perspective Virtual Campus at the OMERACT 10 International Conference, Kota Kinabalu, Malaysia 2010.*

Keynote Speaker

1. **Harrison M.** Incentivized care for chronic diseases. Keynote Presentation. *Arthritis Research Centre of Canada Research Retreat, Richmond, BC. June 18, 2015.*

Discussant

1. Health Economics Methodology Meeting, Vancouver, 2024
2. Vancouver Health Economics Methodology Meeting, Vancouver, 2015, 2017, 2018
3. Health Economists' Study Group. Manchester, England. 2016
4. European Health Economics Association. Paris, France. 2015
5. Health Economists' Study Group. Aix-en-Provence, France. 2012
6. Nordic Health Economists' Study Group. Kuopio, Finland. 2012

10. SERVICE TO THE UNIVERSITY

(a) *Memberships on committees, including offices held and dates*

Committee	Role	Start Date	End Date
Graduate Admissions Committee, Faculty of Pharmaceutical Sciences	Chair	2024/7	Active
Graduate Management Committee, Faculty of Pharmaceutical Sciences	Member	2024/7	Active
UBC Four Year Fellowship (4YF) Adjudication	Member	2024/4	2024/5
UBC Pharmaceutical Sciences VidAdmissions	Reviewer	2024/4	2024/5
Strategic Plan Implementation Investment Fund (SPIIF), Review Committee (Faculty representative)	Member	2024/2	2024/4
Graduate Admissions Committee, Faculty of Pharmaceutical Sciences	Member	2024/1	2024/7
Research Committee: Tamara Mihic, PhD candidate, Faculty of Pharmaceutical Sciences	Chair	2023/9	Active
Research Committee: Jeenat Mehareen, PhD candidate, Faculty of Pharmaceutical Sciences	Chair	2023/9	Active
Search Committee for Assistant/Associate Professor (Health Outcomes)	Member	2022/8	2023/1
BC Government Scholarship Committee	Chair	2022/5	2022/6
2022 UBC Four Year Fellowship (4YF)	Chair	2022/5	2022/6
Search Committee for Assistant/Associate Professor (Data Science)	Member	2022/1	2022/6
Research Committee: Tri Minh Van, PhD candidate, Faculty of Pharmaceutical Sciences	Chair	2022/2	Active
Search Committee for Assistant/Associate Professor (Health Outcomes)	Member	2021/8	2021/12
Search Committee for Assistant/Associate Professor (Data Science)	Member	2021/8	2021/12
Research Committee: Louis Lin, PhD candidate, Faculty of Pharmaceutical Sciences	Chair	2021/9	2021/9
2021-22 BC Government Scholarship Award Committee (MSc)	Member	2021/7	2021/8
Research Committee: Adenike Adelakun, MSc candidate, Faculty of Pharmaceutical Sciences	Chair	2020/9	2022/7
Research Committee: Michael Rowley, PhD candidate, Faculty of Pharmaceutical Sciences	Chair	2020/2	2024/2
Research Committee: Tae Yoon Lee, MSc candidate, Faculty of Pharmaceutical Sciences	Chair	2019/9	Active
Research Committee: Michael Rowley, MSc candidate, Faculty of Pharmaceutical Sciences	Chair	2019/9	2020/9
Examination: Sophie Kitchen, MSc candidate, School of Population and Public Health, Faculty of Medicine	Chair	2019/7	2019/7
Graduate Admissions Committee, Faculty of Pharmaceutical Sciences	Member	2019/1	2022/6
Research Committee: Griffin Pauli, MSc candidate, Faculty of Pharmaceutical Sciences	Chair	2018/9	2020/8
Entry-to-Practice PharmD Electives Working Group	Chair	2017/1	2018/2
Mitchell-Dwivedi Graduate Award Committee (Entrance Award Scholarship Committee)	Member	2016/3	2016/6
Graduate Program Review Working Group	Member	2015/11	2016/3

2015-16 Four Year Doctoral Fellowship (4YF) Adjudication Committee	Member	2015/6	2015/7
Search Committee for Assistant/Associate Professor	Member	2015/3	2016/3
Faculty-Student Engagement Program Management Committee	Member	2015/5	2016/9

(b) Other service, including dates

Service Description	Role	Start Date	End Date
Peer Evaluation of Teaching: Dr Adam Frankel	Evaluator	2024/1	2024/3
Multiple Mini-Interviews (MMIs), Pharmaceutical Sciences	Interview Reviewer	2021/5	2021/5
BPSc Admission Interview Screening	Interview Reviewer	2021/4	2021/5
Faculty of Graduate and Postdoctoral Studies Spring Graduate Awards Competition	Adjudicator	2020/5	2020/6
Multiple Mini-Interviews (MMIs), Pharmaceutical Sciences	Interview Reviewer	2020/5	2020/5
10 th Health Economics and Simulation Modelling Academic Community Half Day	Organizer	2019/12	2020/2
Faculty of Pharmaceutical Sciences Internal Peer Review Program	Reviewer	2019/7	2019/8
Senior PhD Podium Presentations, Pharmaceutical Sciences Research Day and Awards Ceremony	Head Judge	2019/5	2019/5
Collaborations for Outcomes Research and Evaluation (CORE) Annual Retreat	Co-organizer	2019/1	2019/5
Peer Evaluation of Teaching: Dr Annalijn Conklin	Evaluator	2019/1	2019/2
Summer Student Research Program	Coordinator	2017/1	2020/9
Faculty-Student Engagement Program, for 1 st year Undergraduate students on the Entry-to-Practice PharmD	Faculty Liason	2015/9	2020/8
MSc Poster Presentations, Pharmaceutical Sciences Research Day and Awards Ceremony	Head Judge	2015/5	2015/5
Interview panel – Finance Manager	Member	2015/4	2015/4

11. SERVICE TO THE COMMUNITY

(a) Memberships on scholarly societies, including offices held and dates

Scholarly Society	Role	Start Date	End Date
Canadian Association for Health Services and Policy Research	Member	2024/2	Active
Society for Medical Decision Making (44th Annual North American Meeting)	Mentor, One-to-One Mentoring program	2024/1	2024/3
	<i>Trainees and junior faculty to meet and get advice and mentorship from established members of SMDM. The focus of the one-to-one mentoring includes discussions on career development, pathways to success in medical decision-making, advice and insight about professional development, or how to become more involved in SMDM activities.</i>		
Society for Clinical Trials	Member	2022/5	Active
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)	Faculty Advisor University of British Columbia Student Chapter	2021/10	Active
	<i>Support students in the UBC network of ISPOR, which aims to support and develop future leaders in health economics and outcomes research.</i>		
CHSPR Conference 2020: Private Parts Vancouver March 2020	Co-organizer	2019/9	2020/3
	<i>Review of all abstracts submitted to the conference, participation in review committee and adjudication of poster presentation program</i>		
Society for Medical Decision Making 2018 (Montreal, QC) 2019 (Portland, OR)	Scientific Co-Chair	2017/12	2019/10
	<i>Coordinating abstract review, making final decisions, and planning the overall program. Specific duties: (1) reviewing call for abstracts, testing abstract submission site, (2) promoting call for abstracts, (3) calculating normalized z-scores within each reviewer and reviewer-specific z-scores, (4) assessing and answering questions, (5) slotting abstracts into oral and poster sessions, developing "themed" oral sessions, (6) inviting session co-chairs and discussants, (7) reviewing the online abstract program</i>		
Clinical Therapeutics' Working Group: Interdisciplinary Study of Preclinical Prevention of RA	Health Economics and Patient Perspective Member	2018/6	2021/5
Pan-American Society for the Prevention of Rheumatoid Arthritis (PASPORA)	Decision Making & Preference Studies Member	2018/5	2021/5
	<i>As part of this role I presented at the International Summit and Workshop on Pre-autoimmunity and the Prevention of Rheumatic Diseases at Yale University (May 2021)</i>		
Canadian Institutes of Health Research (CIHR) College of Reviewers	Invited Member	2018/2	Active
	<i>I was nominated and invited in recognition of my accomplished career, demonstrated track record of excellence, and dedication to peer review. Acceptance of the invitation identifies me as an engaged and devoted experts in their fields who is committed to supporting peer review excellence and agrees to contribute to peer review processes when available.</i>		

The Canadian Scleroderma Stem Cell Transplant Research Group (CanSSCeT-RG)	Health Economist	2017/10	Active
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)	Member	2015/6	Active
Society for Medical Decision Making (SMDM)	Member	2014/1	Active
Canadian Rheumatology Association	Member	2014/7	Active
Vancouver Health Economics Methodology Meeting (HEMM)	Member	2014/7	Active
International Health Economics Association (iHEA)	Member	2010/1	Active
Health Economists' Study Group (HESG), UK	Member	2008/9	2016/9
Outcome Measures in Rheumatology (OMERACT)	Member	2008/1	2011/12

(b) Memberships on other societies, including offices held and dates

Society	Role	Start Date	End Date
Outcome Measures in Rheumatology (OMERACT)	Invited Fellow Quality-Adjusted Life Years (QALY) Special Interest Group	2009	2011
Outcome Measures in Rheumatology (OMERACT)	Fellow Towards a reference approach to derive QALYs for economic evaluations in rheumatology': University of Toronto, Canada.	2008	2009

(c) Memberships on scholarly committees, including offices held and dates

Scholarly Committee	Role	Start Date	End Date
NIHR (UK) Oversight Group The Christie NHS Foundation Trust (UK)	Steering Committee Member	2024/3	Active
	<i>Health and Social Care Delivery Research (HSDR) Project NIHR155944 - Initial study to compare the carbon footPRINT, patient experience and resources of standard and hypofractionated radiotherapy (IMPRINT)</i>		
MITACS Accelerate Program	Reviewer	2024/2	2024/5
	Invited as specialist reviewer for one health economics application.		
Canadian Institutes of Health Research (CIHR) Improving Health and Admin Data and Monitor Rare Diseases	Review Panel Member	2024/2	2024/5
	<i>Commitment (1) Review of 4 full applications and assessment/scoring (2) Attendance of online (face-to-face) review panel meeting over 1 day.</i>		
Dutch Research Council Domain: Health Research and Development (NWO/ZonMw)	Reviewer Talent Programme Veni	2023/2	2023/3
	Invited to review application based on disease area (arthritis) and methodological (health economics) expertise.		

Canadian Institutes of Health Research (CIHR) Project Scheme (Spring 2023)	Review Panel Member	2022/9	2022/11
	<i>Commitment (1) Review of 9 full applications and assessment/scoring (2) Attendance of online (face-to-face) review panel meeting in November 2022 over 3 days.</i>		
MRC (UK) Clinician Scientist Fellowships	Reviewer	2022/5	2022/6
	<i>Invited reviewer for application which combined my international reputation in health economics and the diagnosis and prevention of inflammatory autoimmune disease. One application.</i>		
The Arthritis Society Graduate Salary and Postdoctoral Fellowship Awards	Chair, Training Awards Panel	2022/7	2022/7
	<i>Chair for six applications</i>		
The Arthritis Society Graduate Salary and Postdoctoral Fellowship Awards	Reviewer	2021/4	2021/7
	<i>Review and report on allocated applications, and participate in review panel teleconference. Nine applications.</i>		
The Arthritis Society Graduate Salary and Postdoctoral Fellowship Awards	Chair, Training Awards Panel	2020/7	2020/7
	<i>Chair for five applications</i>		
Canadian Institutes of Health Research (CIHR) Project Scheme (Spring 2020)	Review Panel Member	2020/5	2020/8
	<i>Commitment (1) Review of 9 full applications and assessment/scoring (2) Attendance of online (face-to-face) review panel meeting over 3 days.</i>		
The Arthritis Society Graduate Salary and Postdoctoral Fellowship Awards	Reviewer	2020/4	2020/7
	<i>Review and report on allocated applications, and participate in review panel teleconference. 6 applications.</i>		
CHSPR Conference 2020: Private Parts	Scientific Review Committee Member	2020/1	2020/3
	<i>Review of all abstracts submitted to the conference, participation in the review committee and adjudication of the poster presentation program.</i>		
Canadian Institutes of Health Research (CIHR) COVID-19 Rapid Research Funding Opportunity 2020	Reviewer	2020/6	2020/7
	<i>Conduct reviews online through ResearchNet, engage in teleconferences to perform discrepancy reviews on applications that have a wide gap amongst reviewers' overall scores. Eight applications.</i>		
Canadian Institutes of Health Research (CIHR) Project Scheme (Spring 2019)	Review Panel Member	2019/9	2019/11
	<i>Commitment (1) Review of 11 full applications and assessment/scoring (2) Attendance of face-to-face review panel meeting in Ottawa.</i>		
Michael Smith Foundation for Health Research Scholar Award 2019 Competition	Scientific Officer	2019/4	2019/4
	<i>Take official notes of the review panel's discussion of each application, ensure the review panel functions smoothly, effectively, and objectively in accordance with MSFHR's policies and procedures related to the review. I am responsible for finalizing and posting the scientific officer notes directly to MSFHR ApplyNet within five days of the review panel.</i>		
Health Research Council of New Zealand (HRC) March 2019 Breast Cancer Register Partnership	Reviewer	2019/3	2019/3
	<i>Commitment: detailed comments and score of multiple full applications, with round of rebuttals.</i>		
International Society of Shared Decision Making International Meeting (Quebec City 2019)	Scientific Review Committee Member	2019/2	2019/3

Michael Smith Foundation for Health Research Scholar Award 2018 Competition	Scientific Officer	2018/4	2018/4
<i>Take official notes of the review panel's discussion of each application, ensure the review panel functions smoothly, effectively, and objectively in accordance with MSFHR's policies and procedures related to the review. I am responsible for finalizing and posting the scientific officer notes directly to MSFHR ApplyNet within five days of the review panel.</i>			
Canadian Institutes of Health Research (CIHR) Project Scheme (Spring 2018)	Review Panel Member	2018/4	2018/6
<i>Commitment (1) Review of nine full applications and assessment/scoring (2) Attendance of face-to-face review panel meeting in Ottawa.</i>			
Canadian Institutes of Health Research (CIHR) Project Scheme (Fall 2017)	Review Panel Member	2017/9	2017/11
<i>Commitment (1) Review of nine full applications and assessment/scoring (2) Attendance of face-to-face review panel meeting in Ottawa.</i>			
Netherlands Organization for Scientific Research 2017 Innovational Research Incentives Scheme	Panel Member	2017/4	2017/6
<i>Selected as expert reviewer for grant on communicating risk in Discrete Choice Experiments based on my publication, grant, and research program.</i>			
Canadian Initiative for Outcomes in Rheumatology Care (CIORA) 2016 Grant Review Panel.	Review Panel Member	2016/5	2016/5
<i>Commitment (1) Pre-review teleconference meeting (60 minutes in length) (2) Reviewers are assigned 4-5 grants after the pre-review teleconference and have 3 weeks to review grants and post their scores online with comments. Each reviewer is the primary reviewer on 2 grants and 2-3 grants as a secondary reviewer. (3) Each reviewer is also required to read the remaining grants and score these online. (4) Grant Review teleconference - 3-4 hours, summarize grants reviewed as the primary reviewer for the Review Panel prior to a subsequent full-group discussion.</i>			
Association of Faculties of Pharmacy of Canada Conference (Richmond, BC)	Chair, Review Committee	2016/1	2016/4
Canadian Institutes of Health Research (CIHR) Project Scheme (Fall 2016)	Review Panel Member	2016/2	2016/4
<i>Commitment: Review of 11 full applications and assessment/scoring</i>			
International Health Economics Association	Member, Scientific Committee	2015/3	2015/7
NIHR Programme Grants for Applied Research, UK	Reviewer	2010/6	2010/9

(d) Memberships on other committees, including offices held and dates

Committee	Role	Start Date	End Date
British Columbia Ministry of Health Drugs Benefit Council (DBC)	Expert Health Economist	2024/7	Active
	<i>The DBC review is to make recommendations about patented and generic drugs, and biologics and biosimilars, to make sure the PharmaCare coverage is fair and sustainable. The DBC meets once per month, and typically discusses two drugs. Significant preparation time is required prior to each meeting, for example, each drug has a report of approximately 50 pages to support discussions. Members are required to attend all meetings.</i>		
British Columbia Ministry of Health Health Technology Assessment Committee (Health Technology Reviews)	Expert Reviewer	2024/3	2024/5
	Report "Estimating the marginal productivity of health spending in BC"		
Government of Yukon Health and Social Services Population Health Sub Committee	Expert Health Economist	2020/2	2020/4
	<i>Health economics evidence review to inform decision about which policies to address social determinants of health would likely yield the biggest impact to system cost and population outcomes for Yukoners</i>		
Government of Yukon Health and Social Services Review of Health and Social Care System	Expert Health Economist	2020/1	2020/4
	<i>As part of a comprehensive review of the Yukon health and social care system, the Yukon government and their expert panel sought additional expert economics-oriented help in this review.</i>		
British Columbia Ministry of Health Health Technology Assessment Committee (Health Technology Reviews)	Expert Health Economist Multi-Criteria Decision Analysis Working Group	2018/12	2020/3
	<i>The aim of this working group was to review the weighting of components of the Health Technology Assessment Committee scoring sheets used for evaluating each technology reviewed by this BC Ministry of Health Committee. I raised concerns about the lack of explicit weights at the outset of my involvement in this committee; the absence of explicit weights may result in implicit weights being applied which do not adequately represent the values of the population of British Columbia for whom we make these resource allocation decisions.</i>		
Canadian Rheumatology Association Human Resource Committee	Health Economics Member	2018/9	2021/9
	<i>The committee develops position statements on HR resource issues for use in political advocacy, continue the successful summer studentship program and evaluation of the program. The role also included a 'Stand Up and Be Counted 2020 survey' to examine the current state of rheumatology practice across Canada, curate HR related research and ensure the CRA membership is aware of this work.</i>		
British Columbia Ministry of Health	Expert Health Economist	2017/7	2024/7

<p>Health Technology Assessment Committee (Health Technology Reviews)</p>	<p><i>The aim of the health technology review is to make recommendations about the public provision of non-drug health technologies that will contribute to maintaining and improving the health and well-being of British Columbians and provide value for money. I am the health economist on the panel, one of five professional members. The Health Technology Assessment Committee holds health technology review meetings as required to carry out its responsibilities and to consider all submissions made to it, typically at least one meeting each month. Significant preparation time is required of members prior to each meeting, for example each meeting has a technology review of approximately 150 pages to support discussions. Members are required to attend all health technology review meetings.</i></p>
---	---

(e) Editorships (list journal and dates)

Journal	Role	Start Date	End Date
<p>The Patient – Patient Centered Outcomes Research</p>	<p>Honorary Editorial Board Member</p> <p><i>Membership of the editorial board includes peer review, attendance of editorial board webinars, input for the direction and content of the journal, and writing editorial pieces or articles.</i></p>	<p>2023/3</p>	<p>Active</p>
<p>Current Rheumatology Reports</p>	<p>Section Editor (Health Economics and Quality of Life)</p> <p><i>I led the Health Economics and Quality of Life sections of this journal, which involved identifying priority topics and identifying and inviting experts to write articles on these topics. I was able to use conference attendance to identify priority topics.</i></p>	<p>2014/6</p>	<p>2017/6</p>
<p>BMC Health Services Research</p>	<p>Associate Editor</p> <p><i>I was responsible for assessing manuscripts for their suitability for peer review, selecting reviewers, and recommending decisions based on the peer reviewer reports and my recommendations. This role involved a commitment to handle at least 12 manuscripts per year.</i></p>	<p>2011/1</p>	<p>2016/9</p>

(f) Reviewer (journal, agency, etc. including dates)

<p>BMJ (British Medical Association Journal)</p>	<p>2024 - ongoing</p>
<p>Canadian Medical Association Journal</p>	<p>2018 - ongoing</p>
<p>Journal of Patient-Reported Outcomes</p>	<p>2017 - ongoing</p>
<p>PLOS ONE</p>	<p>2016 - ongoing</p>
<p>Medical Decision Making</p>	<p>2014 - ongoing</p>
<p>Current Rheumatology Reports</p>	<p>2014 – 2016</p>
<p>Health Economics</p>	<p>2013 - ongoing</p>
<p>Paediatrics</p>	<p>2012</p>
<p>Value in Health</p>	<p>2011 - ongoing</p>
<p>Pharmacoeconomics</p>	<p>2010 - ongoing</p>
<p>Social Science & Medicine</p>	<p>2010 - ongoing</p>
<p>Implementation Science</p>	<p>2009</p>

Patient Education and Counseling	2008 - ongoing
Current Medical Research & Opinion	2007
Quality of Life Research	2006 - 2010
Arthritis Care & Research	2005 - ongoing
Annals of the Rheumatic Diseases	2005 - ongoing
Rheumatology	2004 - ongoing
The Journal of Rheumatology	2004 - ongoing
Archives of Diseases in Childhood	2004

(g) External examiner (indicate universities and dates)

Student Name	University	Faculty	Program Type	Date
Richard Musoke	University of British Columbia	Population and Public Health	PhD	7 th March 2024
Sonia Singh	University of Melbourne (Australia) / UC Davis (USA)	Pediatric Emergency Medicine	PhD	3 rd December 2022
Ryan Dwyer	University of British Columbia	Psychology	PhD	4 th August 2022
William Hall	University of British Columbia	Population and Public Health	PhD	13 th September 2022
Dan Kelleher	National University of Ireland, Galway	Economics	PhD	2 nd March 2022
Wen Shi Alice Yu	University of Technology Sydney (Australia)	Health Economics Research and Evaluation	PhD	26 th January 2022
Suz Jack Chan	University of Otago (New Zealand)	School of Pharmacy	PhD	18 th November 2021
Nevena Rebic	University of British Columbia	Pharmaceutical Sciences	MSc	10 th August 2020
Tamunoibim Sambo	Simon Fraser University	Faculty of Health Sciences	MSc	15 th April 2020
Mohammad Atiquzzaman	University of British Columbia	Pharmaceutical Sciences	PhD	25 th November 2019
Laura Timmis	University of Bangor (UK)	Health Economics and Medicines Evaluation	PhD	11 th October 2019
Nelson Gorrin	University of British Columbia	Pharmaceutical Sciences	PhD	9 th August 2019
Jody Church	University of Technology Sydney (Australia)	Health Economics Research and Evaluation	PhD	October 25 th 2018
Rita McCracken	University of British Columbia	Experimental Medicine	PhD	17 th August 2018
Shahrzad Salmasi	University of British Columbia	Pharmaceutical Sciences	MSc	9 th April 2018
Lingyi Li	University of British Columbia	Experimental Medicine	MSc	27 th September 2017
Sharan Rai	University of British Columbia	Experimental Medicine	MSc	22 nd August 2016
Zafar Zafari	University of British Columbia	Experimental Medicine	PhD	30 th September 2014

(h) Consultant (indicate organization and dates)

- 2019/6 **China National Healthcare Security Administration delegation visit to Vancouver.** Consultant and presenter at “Public Health Insurance Programs in Canada and China: A Comparative Perspective” on behalf of the Centre for Health Evaluation and Outcomes Sciences and the BC Ministry of Health’s Health Technology Assessment Committee.
- 2017/5 **Roche Utility Study Advisory Board,** Telconference
- 2016/9 **Pfizer Health Technology Assessment Consult Meeting,** Montreal.
- 2010/1 - 2012/1 **Frontline Advisor and Health Economics Advisor,** Consultation Service, The NIHR Research Design Service North,
- 2011/1 - 2011/12 **Consultancy,** Consultation Service, Greater Manchester and Cheshire Stroke Network

12. AWARDS AND DISTINCTIONS

(a) Awards for Teaching (indicate name of award, awarding organizations, date)

- 2021 **Teacher of the Year, Nomination. Faculty of Pharmaceutical Sciences.**
Nominated by students following the conclusion of the 2020W term for my teaching of PHRM100 (“May have made the best adaptation to teaching online”) and PHRM332 (“Took to teaching virtually probably the best of any professor”).
- 2018 **Faculty of Graduate and Postdoctoral Studies' #UBC #GreatSupervisor campaign.** Nominated as great supervisor. The 2018 UBC #GreatSupervisor campaign ran from May 7-13th. During this week, we encouraged graduate students to offer thanks to their graduate supervisors on social media (using #UBC #GreatSupervisor) or by survey.

(b) Awards for Scholarship (indicate name of award, awarding organizations, date)

Name of Award	Organization	Value	Date
Fulbright Canada Traditional Scholar Award* (University of California, Davis)	The Fulbright Program	\$18,500	2023
UCLouvain Fond Special de Recherche (Visiting Researcher Award)	UC Louvain, Belgium	\$4415 (€3000)	2023
Japan College of Rheumatology Travel Award	Japan College of Rheumatology	\$2400	2023
Scholar Award	Michael Smith Foundation for Health Research	\$450,000	2017
Young Investigator Salary Award	The Arthritis Society	\$180,000	2016
New Investigator Research Award	Association of Faculties of Pharmacy of Canada	\$500	2016
European League Against Rheumatology Travel Bursary	European League Against Rheumatology (EULAR)	€1800	2009
Postgraduate Student of the Year	University of Manchester	N/A	2008
OMERACT Fellow (Quality-adjusted Life Years Expert Working Group)	Outcome Measures in Rheumatology (OMERACT)	\$10,000	2008
Masters Advanced Course Studentship	Medical Research Council (UK)	\$100,000	2002

*Declined

(c) Awards for Service (indicate name of award, awarding organizations, date)

(d) Other Awards

THE UNIVERSITY OF BRITISH COLUMBIA
Publications Record

SURNAME: HARRISON

FIRST NAME: Mark
MIDDLE NAME(S): James

Initials: MJH
Date: September 2024

1. REFEREED PUBLICATIONS

(a) *Journals*

Summary

Citations: 1920 (Scopus), 3044 (Google Scholar)
h-index: 24 (Scopus), 31 (Google Scholar)
ORCID iD: <https://orcid.org/0000-0002-2115-2447>

	Career	Since 2014 (UBC)
First author (FA)	22	5
First (FA) & Senior author (CA)	0	3
Senior author (SA)	26	25
Contributing author (CA)	58	47
Total	106	77

Key to my contribution

[My contribution], where ‘My contribution’ is classified as:

FA - First Author - typically performed the majority of the experiments in the manuscript, wrote the first draft

CA - Contributing Author – typically helped with experimental design, completed some experiments, edited the draft manuscript

SA - Senior Author – typically conceived the experimental approach, supervised the writing of the manuscript, and corresponding author for the paper

Underline Student/trainee under my supervision

Italic – My doctoral supervisor

A list of Impact Factors and category ranks of the journals I have published in is provided at the end (page 44)

1. Au S, Law MR, Cheng L, McGrail K, **Harrison M**. The impact of reference pricing on prescribing patterns, costs, and health services utilization of proton pump inhibitors: A quasi-experimental study in British Columbia, Canada. *Health Policy*. 2024. Jun;144:105061. doi: 10.1016/j.healthpol.2024.105061. Epub 2024 Apr 4. [CA]
2. Ambasta A, Holroyd-Leduc JM, Pokharel S, Mathura P, Wei-Yeh Shih A, Stelfox HT, Ma I, **Harrison M**, B Manns, Faris P, Williamson T, Shukalek C, Santana M, Omodon O, McCaughey D, Kassam N, Naugler C. Re-Purposing the Ordering of Routine Laboratory Tests in Hospitalized Medical Patients (RePORT): protocol for a multicenter stepped-wedge cluster randomised trial to evaluate the impact of a multicomponent intervention bundle to reduce laboratory test over-utilization. *Implementation Science*. 2024 Jul 2;19(1):45. doi: 10.1186/s13012-024-01376-6 [CA]
3. Biln N, Bansback N, Shojanian K, Puil L, **Harrison M**. A scoping review of triage approaches for the referral of patients with suspected inflammatory arthritis, from primary to rheumatology care. *Rheumatology International*. 2024. Mar 26. doi: 10.1007/s00296-024-05575-8 [SA]
4. Trenaman L, Guh D, Law M, Cheng L, **Harrison M**. Effect of a billing code to reimburse nurse-supported rheumatology care on health care costs and access: an interrupted time series analysis. *Arthritis Care & Research*. 2024. Feb 76(7):936-942. doi: 10.1002/acr.25317. [SA]

5. Yu M, **Harrison M**, Bansback N. Can Prediction Models for Hospital Readmission be Improved by Incorporating Patient-Reported Outcome Measures? A Systematic Review and Narrative Synthesis. *Quality of Life Research*. 2024. Jul;33(7):1767-1779. doi: 10.1007/s11136-024-03638-8. [CA]
6. Thomas M, Verma V, Gheshlaghi N, Esdaile J, Avina-Zubieta A, Barnabe C, **Harrison M**, De Vera MA. Reporting of determinants of health inequities and participant characteristics in randomized controlled trials of systemic lupus erythematosus in Canada: A scoping review. *Lupus*. 2024. Apr 33(5):462-469. doi: 10.1007/s11136-024-03638-8. [CA]
7. Biln N, Guh D, Bansback N, Shojania K, **Harrison M**. The Association of Rheumatologist Supply and Multidisciplinary Care With Timely Patient Access to Rheumatologists: Evidence From British Columbia, Canada. *Arthritis Care & Research*. 2024 Apr 76(4):444-453. doi: 10.1002/acr.25274. [SA]
Selected to feature in The Rheumatologist, a newsletter of summaries of manuscripts selected by the editor with a high degree of clinical or public health relevance. <https://www.the-rheumatologist.org/article/3-acr-study-summaries-frailty-prefrailty-in-ra-premature-mortality-in-gout-using-recruitment-multidisciplinary-care-incentives-to-improve-access/>
8. Trenaman L, **Harrison M**, Hoch J. What is a star worth to Medicare beneficiaries? A discrete choice experiment of hospital quality ratings. *Health Affairs Scholar*. 2024 Jan 1. 2(1). doi:10.1093/haschl/qxad085 [CA]
9. Gheshlaghi N, Thomas M, **Harrison M**, De Vera MA. Reporting of determinants of health inequities and participant characteristics in randomized controlled trials of juvenile idiopathic arthritis in Canada: A scoping review. *Pediatric Rheumatology*. 2023 Nov 6;21(1):134. doi: 10.1186/s12969-023-00917-5. Accepted. [CA]
10. Hamilton MM, C-W C Lin, Arora S, **Harrison M**, Tracy M, Nickel B, Abdel Shaheed C, Gnjidic D, Mathieson S. Understanding general practitioners' prescribing choices to patients with chronic low back pain: a discrete choice experiment. *International Journal of Clinical Pharmacy*. 2024. Feb; 46(1):111-121. doi: 10.1007/s11096-023-01649-y [CA]
11. **Harrison M**. Sex in the Time of COVID-19. *Journal of Rheumatology*. 2023 Oct;50(10):1208-1210. doi: 10.3899/jrheum.2023-0444. [FA] [SA]
12. Trenaman L, **Harrison M**, Hoch J. Medicare beneficiaries' perspectives on the quality of hospital care: Implications for value-based payment. *JAMA Network Open*. 2023 Jun; 6(6): e2319047. doi: 10.1001/jamanetworkopen.2023.19047 [CA]
13. Trenaman L, Kaal KJ, Laba T-L, Safari A, Aguiar M, Burch T, Beckett J, Munro S, Hudson M, **Harrison M**. The financial burden to access care for Canadians with scleroderma: results of a cross-sectional survey. *CMAJ Open*. 2023 July 11(4) E630-E636; doi: <https://doi.org/10.9778/cmajo.20220227>. [SA]
14. Metcalfe RK, **Harrison M**, Singer J, Lewisch M, Lee T, von Dadelszen P, Magee LA, Bansback N & the CHIPS Study Group. Using a Patient-Centered Composite Endpoint in a Secondary Analysis of the Control of Hypertension in Pregnancy Study (CHIPS) Trial. *Trials*. 2023 Feb 24(1):99. doi: 10.1186/s13063-023-07118-1. [CA]
15. McClellan A, Cheng L, Bansback N, Clement F, Tadrous M, **Harrison M**, Law M. Uptake and spending on biosimilar infliximab and etanercept after new start and switching policies in Canada: An interrupted time series analysis. *Arthritis Care & Research*. 2023 Sep 75(9):2011-2021. doi: 10.1002/acr.25099 [CA]
16. Hazlewood GS, Colmegna I, Hitchon C, Fortin PR, Bernatsky S, Clarke AE, Mosher D, Wilson T, Thomas M, Barber C, **Harrison M**, Bansback N, Proulx L, Richards DP, Kaplan GG. Preferences for COVID-19 vaccination in people with chronic immune-mediated inflammatory diseases. *Journal of Rheumatology*. 2023 Jul;50(7):949-957. doi: 10.3899/jrheum.220697. [CA]

17. Fleischer C, Bemis E, Feser ML, Kormendi VA, Zhang A, Ketcham K, White SD, Striebich CC, Deane KDD, **Harrison M**. Preferences and Insights for Participation in a Rheumatoid Arthritis Clinical Prevention Trial: A Mixed Methods Study, *ACR Open Rheumatology*. 2022 Nov;4(11):974-982. doi: 10.1002/acr2.11500. [SA]
18. Thomas M, **Harrison M**, De Vera M. Reporting of determinants of health inequities in rheumatoid arthritis randomized controlled trials in Canada: A scoping review. *Arthritis Care & Research*. 2022. Jan 75(1):101-114. doi: 10.1002/acr.24978. [CA]
19. Apantaku GO, McDonald PJ, Aguiar M, Cabrera LY, Chiong W, Connolly MB, Hrincu V, Ibrahim GM, Kaal KJ, Lawson A, Naftel R, Racine E, Safari A, Illes, J, **Harrison M**. Clinician preferences for neurotechnologies in pediatric drug resistant epilepsy: a discrete choice experiment. *Epilepsia*. 2022. 63(9): 2838-2349. DOI: 10.1111/epi.17328 [SA]
20. McClellan A, Law MR, **Harrison M**, Bansback N, Gomes T, Tadrous M. Uptake of biosimilar drugs in Canada: Analysis of provincial policies and usage data. *CMAJ*. 2022. 194(15): E556-E560. DOI: 10.1503/cmaj.211478 [CA]
Cited in: BC Ministry of Health. B.C.'s Biosimilars Initiative: A Report on Patient and Financial Impact [Internet]. 2024 [cited 2024 Jun 16]. Available from: https://news.gov.bc.ca/files/BCBiosimilarsInitiativeAReportonPatientandFinancialImpact_June%202024.pdf
21. Duncan R, Cheng L, Law MR, Shojania K, De Vera MA, **Harrison M**. The impact of introducing multidisciplinary care assessments on access to rheumatology care in British Columbia: an interrupted time series analysis. *BMC Health Services Research*. 2022.22(1):327. DOI: 10.1186/s12913-022-07715-x [SA]
22. Chew C, Aguiar M, Bansback N, Law MR, **Harrison M**. Patient perspectives on the British Columbia Biosimilars Initiative: a qualitative descriptive study. *Rheumatology International*. 2022. 42(10): 1831-1842. DOI: 10.1007/s00296-021-04874-8 [SA]
23. Kulhawy-Wibe SC, Widdifield J, Lee JJY, Thorne JC, Yacyshyn EA, Batthish M, Jerome D, Shupak R, Jiline K, Purvis J, Shamis J, Roberts J, Kur J, Burt JE, Johnson NA, Barnabe C, Spencer N, **Harrison M**, Pope J, Barber CEH. Results from the 2020 Canadian Rheumatology Association's Workforce and Wellness Survey. *J Rheum* 2022. 49(6): 635-643. DOI: 10.3899/jrheum.210990 [CA]
24. Ahmadian S, Sin DD, Lynd LD, **Harrison M**, Sadatsafavi M. A Benefit-Harm Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. *Thorax*. 2022. 77(11): 1079-1087. DOI: 10.1136/thoraxjnl-2021-217962 [CA]
25. Garrett B, Caulfield T, Murdoch B, Brignall M, Kapur A, Murphy S, Reardon J, **Harrison M**, Hislop J, Wilson-Keates B, Anthony J, Loewen P, Musoke R, Braun J. A Taxonomy of Risk Associated Alternative Health Practices: A Delphi study. *Health & Social Care in the Community*. 2022. 30(3) DOI: 10.1111/hsc.13386 [CA]
26. Apantaku G*, Aguiar M*, Kaal KJ, McDonald PJ, Connolly MB, Hrincu V, Illes J, **Harrison M**. Understanding attributes that influence physician and caregiver decisions about neurotechnology for pediatric drug resistant epilepsy: a formative qualitative study to support the development of a discrete choice experiment. *Patient*. 2022. 15(2): 219-232. DOI: 10.1007/s40271-021-00544-w [SA] * Joint first authors.
27. Sigurdsson S, **Harrison M**, Pearce A, Richardson H, Zaza K, Brundage M. One fraction size does not fit all: Patient preferences for hypofractionated radiotherapy from a discrete choice experiment. *Practical Radiation Oncology*. 2022. 12(1): e24-e33. DOI: 10.1016/j.pro.2021.08.012 [CA]
28. Apantaku G, Aguiar M, Kaal KJ, Munro S, Teo M, **Harrison M**. Understanding multidisciplinary care for people with rheumatic disease in BC through patients, nurses and physicians' voices: a qualitative policy evaluation. *BMC Health Services Research*. 2021. 21(1): 1148. DOI: 10.1186/s12913-021-07138-0 [SA]
Listed in the The Arthritis Society's top 10 advances of the year 2021: <https://arthritis.ca/about-us/what-we-do/research/top-10-research-advances-of-2021>

29. [Aguiar M](#), Laba T-L, Munro S, Burch T, Beckett J, [Kaal KJ](#), Bansback N, Hudson M, **Harrison M**. Co-production of randomized clinical trials with patients: a case study in autologous hematopoietic stem cell transplant for patients with scleroderma. *Trials*. 2021. 22(1): 6111. DOI: 10.1186/s13063-021-05575-0 [SA]
30. Hrinco V, McDonald P, Connolly M, **Harrison M**, Ibrahim G, Naftel R, Chiong W, Alam A, Ribary U, Illes J. Choice and Trade-offs: Parent Decision-making for Neurotechnologies for Pediatric Drug Resistant Epilepsy. *Journal of Child Neurology*. 2021. 36(11): 943-949. DOI: 10.1177/08830738211015010 [CA]
31. [Aguiar M](#), **Harrison M**, Munro S, Burch T, [Kaal KJ](#), Hudson M, Bansback N, Laba T. Designing discrete choice experiments using a patient-oriented approach. *Patient* 2021. 14(4): 389-397. DOI: 10.1007/s40271-020-00431-w [SA]
 - a. Published alongside a patient commentary from a member of our research team: Burch T. Patient Commentary: Added value and validity to research outcomes through thoughtful, multifaceted, patient-oriented research. *Patient*. 2021. 14(4): 385-387. DOI: 10.1007/s40271-020-00432-9
32. [Elliot L](#), Frew E, Mollan SP, Mitchell JL, Yiangou A, Alimajstorovic Z, Ottridge RS, Wakerley BR, Thaller M, Grech O, Singhal R, Tahrani AA, **Harrison M**, Sinclair AJ, [Aguiar M](#). Cost-effectiveness of bariatric surgery versus community weight management to treat obesity-related idiopathic intracranial hypertension. *Surgery for Obesity and Related Diseases*. 2021. 17(7): 1310-1316. DOI: 10.1016/j.soard.2021.03.020 [CA]
33. Pollard S, Weymann D, Dunne J, Mayanloo F, Buckell J, Buchanan J, Wordsworth S, Friedman J, Stockler-Ipsiroglu S, Dragojlovic N, Elliott A, **Harrison M**, Lynd L, Regier D. Toward the diagnosis of rare childhood genetic diseases: What do parents value most? *European Journal of Human Genetics*. 2021. 29(10): 1491-1501. DOI: 10.1038/s41431-021-00882-1 [CA]
34. Ho H, Janjua NZ, McGrail KM, **Harrison M**, The BC Hepatitis Testers Cohort Team, Law MR. The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia. *PLoS One*. 2021. 16(3):e0247843 DOI: 10.1371/journal.pone.0247843 [CA]
35. Johnson K, Sadatsafavi M, Adibi A, Lynd L, **Harrison M**, Tavakoli H, Sin D, Bryan S. Cost-Effectiveness of Case Detection Strategies for the Early Detection of COPD. *Applied Health Economics and Health Policy* 2021. 19(2): 203-15 DOI: 10.1007/s40258-020-00616-2 [CA]
36. Pearce A, **Harrison M**, Watson V, Street D, Howard K, Bansback N, Bryan S. Respondent understanding in discrete choice experiments: A scoping review. *Patient*. 2021. 14: 17-53. DOI: 10.1007/s40271-020-00467-y [CA]
37. Cragg JJ, Azouly L, Collins G, De Vera M, Etminan M, Lalji F, Gershon A, Guyatt G, **Harrison M**, Jutzeler C, Kassam R, Kenzerska, Lynd L, Ali Mansournia M, Sadatsafavi M, Tong B, Warner F, Tremlett H. The reporting of observational studies of drug effectiveness and safety: recommendations to extend existing guidelines. *Expert Opinion on Drug Safety*. 2021. 20(1):1-8. DOI: 10.1080/14740338.2021.1849134 [CA]
38. [Kaal, K.J.](#), Bansback, N., Hudson, M. Anis, A., Koehn, C., **Harrison, M**. Patient-Provider Communication about Medication Cost in Rheumatoid Arthritis. *Clinical Rheumatology*. 2021. 40: 93-100 DOI: 10.1007/s10067-020-05188-z [SA]
39. McDonald P, Hrinco V, Connolly M, **Harrison M**, Ibrahim G, Naftel R, Chiong W, Udwadia F, Illes J. Novel neurotechnological interventions for pediatric drug resistant epilepsy: Physician perspectives. *Journal of Child Neurology* 2021. 36(3): 222-229. DOI: 10.1177/0883073820966935 [CA]
40. [Kaal KJ](#), [Aguiar M](#), **Harrison M**, McDonald P, Illes J. The Clinical Research Landscape of Pediatric Drug Resistant Epilepsy. *Journal of Child Neurology*. 2020. 35(11): 763-66. DOI: 10.1177/0883073820931255 [CA]
41. [Turner A](#), Sutton M, **Harrison M**, Hennessey A, Humphrey N. Cost-effectiveness of a school-based social and emotional learning intervention: an indicative trial-based economic evaluation of the Promoting

- Alternative Thinking Strategies curriculum. *Applied Health Economics and Health Policy*. 2020. 18(2): 271-85. DOI: 10.1007/s40258-019-00498-z [CA]
42. **Harrison M**, Bansback N, Aguiar M, Koehn C, Shojania K, Finckh A, Hudson M. Preferences for treatment to prevent rheumatoid arthritis in Canada and the influence of shared-decision-making. *Clinical Rheumatology*. 2020. 39(10): 2931-2941. DOI: 10.1007/s10067-020-05072-w. [FA] [SA]
43. Metcalfe RK, **Harrison M**, Hutfield A, Lewisch M, Singer J, Magee LA, Bansback N. Patient Preferences and Decisional Needs When Choosing a Treatment Approach for Pregnancy Hypertension: A Stated Preference Study. *Canadian Journal of Cardiology*. 2020. 36(5): 775-9. DOI: 10.1016/j.cjca.2020.02.090 [CA]
44. Law MR, Chan FKI, **Harrison M**, Worthington H. The Impact of Brand Drug Discount Cards on Private Insurer, Government, and Patient Expenditures. *Canadian Medical Association Journal*. 2019. 191(45):E1237-E1241. DOI: 10.1503/cmaj.190098 [CA]
45. **Harrison M**, Spooner L, Bansback N, Milbers K, Koehn C, Shojania K, Finckh A, Hudson M. Preventing Rheumatoid Arthritis: Preferences for and Predicted Uptake of Preventive Treatments for Rheumatoid Arthritis Among High Risk Individuals. *PLoS One*. 2019. 14(4):e0216075. DOI: 10.1371/journal.pone.0216075 [SA]
Top 10% most cited papers published in PLoS One 2019
46. Falahee M, Finckh A, Raza K, **Harrison M**. Preferences of patients and at risk individuals for preventive approaches to rheumatoid arthritis. *Clinical Therapeutics*. 2019. S0149-2918(19)30179-1 [CA]
47. Salmasi S, De Vera M, Barry A, Bansback N, **Harrison M**, Lynd LD, Loewen P. Assessment of atrial fibrillation patients' condition and medication knowledge gaps: A systematic review and meta-analysis. *Annals of Pharmacotherapy*. 2019. 53(8):773-785 [CA]
48. Lau Y-S, **Harrison M**, Sutton M. Association Between Symptom Duration and Patient-Reported Outcomes Before and After Hip Replacement Surgery. *Arthritis Care and Research*. 2020. 72(3):423-431 [CA]
49. **Harrison M**, Han PKJ, Rabin B, Bell M, Kay H, Spooner L, Peacock S, Bansback N. Communicating uncertainty in cancer prognosis: A review of web-based prognostic tools. *Patient Education and Counseling* 2019. 102(5): 842-9 [FA]
50. Salmasi S, Kwan L, MacGillivray J, Bansback N, De Vera M, Barry AR, **Harrison M**, Andrade J, Lynd LD, Loewen P. Assessment of atrial fibrillation patients' education needs from both patients' and clinicians' perspectives: a qualitative descriptive study. *Thrombosis Research* 2019. 173: 109-116. [CA]
51. Ling D, Anis A, Lynd L, **Harrison M**, Bansback N. Early economic evaluations for making better decisions to invest in personalized medicine technologies. *Journal of Comparative Effectiveness Research* 2018; 8(1). Published Online:10 Dec 2018. [CA]
52. Humphrey N, Hennesey A, Lendrum A, Wigelsworth M, Turner A, Panayiotou M, Joyce C, Pert K, Stephens E, Wo L, Squires G, Woods K, **Harrison M**, Calam R. The PATHS curriculum for promoting social and emotional well-being among children aged 7-9 years: a cluster RCT. *Public Health Research*. 2018 6(10). [CA]
53. Kaal KJ, **Harrison M**, Whitehurst DGT, Townson A, Dance D, Stoessl AJ, Illes J. Commentary: Operationalizing neuroimaging for disorders of consciousness. *Canadian Journal of Neurological Sciences*. 2018; 45: 633-35 [CA]
54. Munro S, Spooner L, Milbers K, Hudson M, Koehn C, **Harrison M**. Perspectives of patients, first-degree relatives and rheumatologists on preventive treatments for rheumatoid arthritis: A Qualitative Analysis. *BMC Rheumatology*. 2018 2:18. [SA]

55. Hiligsmann M, Rademacher S, Kaal KJ, Bansback N, **Harrison M**. The use of routinely collected patient-reported outcome measures in rheumatoid arthritis. *Seminars in Arthritis and Rheumatism*. 2018. 48(3): 357-366. [SA]
56. **Harrison M**, Quisias J, Frew E, Albon S. A cost-benefit analysis of teaching and learning technology in a Faculty of Pharmaceutical Sciences. *American Journal of Pharmaceutical Education* 2019. 83(6): Article 6834. [SA]
57. Hall J, Kaal KJ, Lee J, Duncan R, Tsao N, **Harrison M**. Patient satisfaction and costs of multidisciplinary models of care in rheumatology: A review of the recent literature. *Current Rheumatology Reports* 2018. 20 (4):19. [SA]
58. Kolhatkar A, Cheng L, Chan F, **Harrison M**, Law MR. Pharmacist medication reviews: Some hopeful comments about a negative finding. *Journal of the American Pharmacists Association* 2017. 57(3) 298-299. (Letter) [CA]
59. **Harrison M**, Milbers K, Hudson M, Bansback N. Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of Discrete Choice Experiments. *BMJ Open* 2017. 7(5), e014719 [SA]
60. Bansback N, Bell M, Spooner L, Pompeo A, Han PKH, **Harrison M**. Communicating uncertainty in benefits and harms: A review of patient decision support interventions. *Patient* 2017. 10(3), 311-319 [SA]
61. **M Harrison**, K Milbers, T Mihic, AH Anis. Incentives in rheumatology: the potential contribution of physician responses to financial incentives, public reporting, and treatment guidelines to health care sustainability. *Current Rheumatology Reports* 2016. 18(7), 1-8. [SA] [FA]
62. Kolhatkar A, Cheng L, Chan F, **Harrison M**, Law MR. The impact of medication reviews by community pharmacists. *Journal of the American Pharmacists Association* 2016. 56(5): 513-520. e1 [CA]
63. Meacock R, Sutton M, Kristensen S-R, **Harrison MJ**. Using survival analysis to improve estimates of life year gains in policy evaluations. *Medical Decision Making* 2016. 37(4): 415-426. [SA]
64. **Harrison MJ**, Marra CA, Bansback N. Preferences for 'new' treatments diminish in the face of ambiguity. *Health Economics* 2016. 26(6): 743-752. [SA]
65. Penton H, Hiligsmann M, **Harrison M**, Reginster JY, Boonen A, Bansback N. Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment. *Osteoporosis International* 2016. 27(9): 2697-2707. [CA]
66. Bansback N, **Harrison M**, Whitehurst DGT, Sadatsafavi M, Stiggelbout A. Attitude to health risk in the Canadian Population: evidence from a nationwide cross-sectional survey. *CMAJ Open* 2016. 4(2): E284. [CA]
67. Bansback N, **Harrison M**, Marra C. Does introducing imprecision around probabilities for benefit and harm influence the way people value treatments? *Medical Decision Making* 2016. 36(4), 490-502. [CA]
68. **Harrison M**, Marra C, Shojania K, Bansback N. Societal preferences for rheumatoid arthritis treatments. Evidence from a discrete choice experiment. *Rheumatology* 2015. 54(10): 1816-1825. [FA]
69. Bansback N, Trenaman L, **Harrison M**. How important is mode of administration in treatments for rheumatic diseases and related conditions? *Current Rheumatology Reports* 2015. 17(6): 1-13. [CA]
70. Frew EJ, **Harrison M**, Rossello Roig M, Martin TPC. Providing an extended use of an otological-specific outcome instrument to derive cost-effectiveness estimates of treatment. *Clinical Otolaryngology* 2015. 40(6): 593-599. [CA]
71. Nikolova S, **Harrison M**, Sutton M. The impact of waiting time on health gains from surgery: Evidence from a national patient reported outcomes dataset. *Health Economics* 2015. 25(8): 955-968. [CA]

72. **Harrison M**, Birch S, Eden M, Ramsden S, Farragher T, Payne K, Hall G, Black GC. Variation in healthcare services for specialist genetic testing and implications for planning genetic services: the example of inherited retinal dystrophy in the English NHS. *Journal of Community Genetics* 2015 6(2), 157-165. [FA]
73. Meacock R, **Harrison M**, McElhone K, Abbott J, Haque S, Bruce I, Teh LS. Mapping the disease-specific LupusQoL to the SF-6D. *Quality of Life Research* 2015; (7):1749-58. [CA]
74. **Harrison MJ**, Dusheiko M, Sutton M, Gravelle H, Doran T, Roland M. Effect of a national primary care pay for performance scheme on emergency hospital admissions for ambulatory care sensitive conditions: controlled longitudinal study. *British Medical Journal* 2014 [FA]
75. Gavan S, **Harrison M**, Iglesias C, Barton A, Manca A, Payne K. Economics of stratified medicine in rheumatoid arthritis. *Current Rheumatology Reports* 2014 Dec;16(12):468. [CA]
76. Heather E, Payne K, **Harrison M**, *Symmons D*. Including adverse drug events in economic evaluations of anti-tumour necrosis factor- α drugs for adult rheumatoid arthritis: A systematic review of economic decision analytic models. *Pharmacoeconomics*. 2014; 32(2):109-34. [CA]
77. **Harrison MJ**, Rigby D, Vass C, Flynn T, Louviere J, Payne K. Risk as an attribute in discrete choice experiments: A systematic review of the literature. *Patient*. 2014; 7(2):151-70. [FA]

Before joining UBC

78. Bujkiewicz S, Thompson JR, Sutton AJ, Cooper NJ, **Harrison MJ**, *Symmons DPM*, Abrams KR. Use of Bayesian multivariate meta-analysis to estimate the HAQ for mapping onto the EQ-5D questionnaire in rheumatoid arthritis. *Value in Health*. 2014; 17(1):109-15. [CA]
79. Bujkiewicz S, Thompson J, Sutton A, Cooper N, **Harrison MJ**, *Symmons D*, Abrams KR. Multivariate meta-analysis of mixed outcomes: A Bayesian approach. *Statistics in Medicine*. 2013; 32(22):3926-43. [CA]
80. Meacock R, Dale N, **Harrison MJ**. The humanistic and economic burden of systemic lupus erythematosus (SLE): A systematic review. *Pharmacoeconomics*. 2013; 31(1):49-61. [SA]
81. **Harrison M**, Ahmad Y, Haque S, Dale N, Teh L, Snowden N, Ho P, Gorodkin R, Bruce I. Construct and criterion validity of the short form-6D utility measure in patients with systemic lupus erythematosus. *Journal of Rheumatology*. 2012; 39(4):735-42. [FA]
82. **Harrison M**, Reeves D, Harkness E, Valderas J, Kennedy A, Rogers A, Hann M, Bower P. A secondary analysis of the moderating effects of depression and multimorbidity on the effectiveness of a chronic disease self-management programme. *Patient Education and Counseling*. 2012; 87(1):67-83. [FA]
83. **Harrison M**, Fullwood C, Bower P, Kennedy A, Rogers A, Reeves D. Exploring the mechanisms of change in the chronic disease self-management programme: Secondary analysis of data from a randomized controlled trial. *Patient Education and Counseling*. 2011; 85(2):e39-e47. [FA]
84. Kirwan J, Boonen A, **Harrison M**, Hewlett S, Wells G, Singh J, Furst D, Dworkin R. OMERACT 10 Patient Perspective Virtual Campus: Valuing Health; Measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health. *Journal of Rheumatology*. 2011; 38(8):1728-34. [CA]
85. **Harrison M**, Bansback N, Marra C, Drummond M, Tugwell P, Boonen A. Valuing health for clinical and economic decisions: Directions relevant for rheumatologists. *Journal of Rheumatology*. 2011; 38(8):1770-5. [FA]

86. Foster H, **Harrison M**, Pain C, *Symmons D*, Baidam E. Delivery of paediatric rheumatology care in the UK – The projected shortfall. *Clinical Rheumatology*. 2011; 30(5):679-83. [CA]
87. Camacho E, **Harrison M**, Farragher T, Lunt M, Bunn D, Verstappen S, *Symmons D*. Parity, time since last live birth and long-term functional outcomes: A study of women participating in the Norfolk Arthritis Register. *Annals of the Rheumatic Diseases*. 2011; 70(4):642-5. [CA]
88. **Harrison MJ**, Lee S, Deighton C, *Symmons DPM*. UK rheumatology consultant workforce provision 2007-9: Results from the BSR/Arthritis Research UK Consultant Workforce Register. *Clinical Medicine*. 2011; 11(2):119-24. [FA]
89. **Barta Z**, **Harrison M**, Wangrangsimakul T, Shelmerdine J, The L, Pattrick M, Edlin H, Dale N, Ahmad Y, Bruce I. Health-related quality of life, smoking and carotid atherosclerosis in white British women with systemic lupus erythematosus. *Lupus*. 2010; 19(3):231-8. [CA]
90. **Harrison M**, Lunt M, Verstappen S, Watson K, Bansback N, *Symmons D*. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. *Health and Quality of Life Outcomes*. 2010; 11(8):21. [FA]
91. **Harrison M**, Boonen A, Tugwell P, *Symmons D*. Same question, different answers: A comparison of global health assessments using visual analogue scales. *Quality of Life Research*. 2009 Dec; 18(10):1285-92. [FA]
92. **Harrison M**, Davies L, Bansback N, McCoy M, Verstappen S, Watson K, *Symmons D*. The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. *Quality of Life Research*. 2009; 18(9):1195-205. [FA]
93. **Harrison M**, Farragher T, Clarke A, Manning S, Bunn D, *Symmons D*. Association of functional outcome with both personal- and area-level socioeconomic inequalities in patients with inflammatory polyarthritis. *Arthritis and Rheumatology*. 2009; 61(10):1297-304. [FA]
94. **Harrison MJ**, Davies LM, Bansback NJ, McCoy MJ, Farragher TM, Verstappen SS, Hassell A, *Symmons D*. Why do patients with inflammatory arthritis often score states “worse than death” on the EQ-5D? An investigation of the EQ-5D classification system. *Value in Health*. 2009; 12(6):1026-34. [FA]
95. Boonen A, Maetzel A, Drumond M, Suarez-Almazor M, **Harrison M**, Welch V, Tugwell P. The OMERACT Initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology. *Journal of Rheumatology*. 2009; 36(9):2045-9. [CA]
96. **Harrison MJ**, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, *Symmons DPM*. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register. *Annals of the Rheumatic Diseases*. 2009; 68(2):209-215. [FA]
97. Bansback N, Brennan A, *Symmons D*, Nixon R, Madan J, **Harrison M**, Watson K. Comment on: Modelling the cost effectiveness of TNF- α antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry: reply. *Rheumatology* 2008. 47(7):1107-1107.(Letter) [CA]
98. **Harrison MJ**, Deighton C, *Symmons D*. An update on the UK rheumatology consultant workforce provision: The BSR/ARC Workforce Register 2005-2007: Assessing the impact of recent changes in NHS provision. *Rheumatology* 2008; 47(7):1065-9. [FA]
99. Bansback N, **Harrison MJ**, Brazier J, Davies L, Kopec J, Marra C, *Symmons D*, Anis A. Health state utility values: A description of their development and application for rheumatic diseases. *Arthritis and Rheumatology* 2008; 59(7):1018-26. [CA]

100. **Harrison MJ**, Davies LM, Bansback NJ, Ingram M, Anis AH, *Symmons D*. The validity and responsiveness of generic utility measures in rheumatoid arthritis: A review. *Journal of Rheumatology* 2008; 35(4):592-602. [FA]
101. Brennan A, Bansback N, Nixon R, Madan J, **Harrison M**, Watson K, *Symmons D*. Modelling the cost effectiveness of TNF- α Antagonists in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry. *Rheumatology* 2007; 46(8):1345-1354. [CA]
102. **Harrison MJ**, Hassell A, Dawes P, Scott D, Knight S, Davis M, Mulherin D, *Symmons D*. The overall status in rheumatoid arthritis (OSRA) measure – further evidence to support its use in clinical practice. *Rheumatology* 2007; 46(5):849-55. [FA]
103. **Harrison MJ**, Morley KD, *Symmons D*. Developments in rheumatology consultant manpower provision: the VSR/ARC Workforce Register 2003-5. *Rheumatology* 2006; 45(11):1416-21. [FA]
104. *Symmons D*, Tricker K, **Harrison MJ**, Roberts C, Davis M, Dawes P, Hassell A, Knight S, Mulherin D, Scott D. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatid drugs – results of the British Rheumatoid Outcome Study Group Randomized Controlled Trial. *Rheumatology* 2006; 45(5):558-65. [CA]
105. **Harrison MJ**, O'Hare A, Campbell H, Adamson A, McNeillage J. Prevalence of autistic spectrum disorders in Lothian, Scotland: An estimate using the “capture-recapture” technique. *Archives of Disease in Childhood* 2006; 91(1):16-9. [FA]
106. **Harrison MJ**, Tricker KJ, Davies L, Hassell A, Dawes P, Scott DL, Knight S, Davis M, Mulherin D, *Symmons DPM*. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. *The Journal of Rheumatology* 2005. 32(12): 2330-2336. [FA]

2022 Web of Science Journal Citation Reports

Journal name	Category	2022 JIF	Rank
ACR Open Rheumatology	RHEUMATOLOGY	3.4	14/54
American Journal of Pharmaceutical Education	EDUCATION, SCIENTIFIC DISCIPLINES	3.3	15/43
Annals of Pharmacotherapy	PHARMACOLOGY & PHARMACY	2.9	163/278
Annals of the Rheumatic Diseases	RHEUMATOLOGY	27.4	2/34
Applied Health Economics and Health Policy	ECONOMICS	3.6	100/380
Archives of Disease in Childhood	PEDIATRICS	5.2	11/130
Arthritis & Rheumatology	RHEUMATOLOGY	13.3	4/34
Arthritis Care & Research	RHEUMATOLOGY	4.7	7/34
BMC Health Services Research	HEALTH CARE SCIENCES & SERVICES	2.8	57/106
BMC Rheumatology	RHEUMATOLOGY	2.2	31/54
BMJ	MEDICINE, GENERAL & INTERNAL	107.7	4/169
BMJ Open	MEDICINE, GENERAL & INTERNAL	2.9	80/169
Canadian Journal of Cardiology	CARDIAC & CARDIOVASCULAR SYSTEMS	7.2	24/143
Canadian Journal of Neurological Sciences	CLINICAL NEUROLOGY	3.2	101/212
Canadian Medical Association Journal (CMAJ)	MEDICINE, GENERAL & INTERNAL	17.4	11/169
Canadian Medical Association Journal (CMAJ) Open	MEDICINE, GENERAL & INTERNAL	N/I	N/A
Clinical Medicine	MEDICINE, GENERAL & INTERNAL	4.4	49/169
Clinical Otolaryngology	OTORHINOLARYNGOLOGY	2.1	22/43
Clinical Rheumatology	RHEUMATOLOGY	3.4	21/34
Clinical Therapeutics	PHARMACOLOGY & PHARMACY	3.2	146/278
Current Rheumatology Reports	RHEUMATOLOGY	5	10/34
Epilepsia	CLINICAL NEUROLOGY	5.6	37/212
European Journal of Human Genetics	GENETICS & HEREDITY	5.2	30/171
Expert Opinion on Drug Safety	PHARMACOLOGY & PHARMACY	3.1	152/278
Health Affairs Scholar	HEALTH POLICY & SERVICES	N/I	N/A
Health and Quality of Life Outcomes	HEALTH POLICY & SERVICES	3.6	23/87
Health and Social Care in the Community	SOCIAL WORK	2.4	12/44
Health Economics	ECONOMICS	2.1	191/380
Health Policy	HEALTH POLICY & SERVICES	3.3	34/87
International Journal of Clinical Pharmacy	PHARMACOLOGY & PHARMACY	2.4	197/278
JAMA Network Open	MEDICINE, GENERAL & INTERNAL	13.8	15/169
Journal of Child Neurology	PEDIATRICS	1.9	74/130
Journal of Community Genetics	GENETICS & HEREDITARY	1.9	129/189
Journal of Comparative Effectiveness Research	HEALTH CARE SCIENCES & SERVICES	2.1	77/106
Journal of Rheumatology	RHEUMATOLOGY	3.7	17/34
Journal of the American Pharmacists Association	PHARMACOLOGY & PHARMACY	2.1	212/278
Lupus	RHEUMATOLOGY	2.6	23/34
Medical Decision Making	HEALTH POLICY & SERVICES	3.6	23/87
Osteoporosis International	ENDOCRINOLOGY & METABOLISM	4	62/145
Patient Education and Counseling	SOCIAL SCIENCES, INTERDISCIPLINARY	3.5	19/110
Patient-Patient Centered Outcomes Research	HEALTH POLICY & SERVICES	3.6	23/87
Pediatric Rheumatology	PEDIATRICS	2.5	53/130
Pharmacoeconomics	ECONOMICS	4.4	71/380
PLoS One	MULTIDISCIPLINARY SCIENCES	3.7	26/73
Practical Radiation Oncology	ONCOLOGY	3.3	119/318
Public Health Research	PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH	N/I	N/A
Quality of Life Research	HEALTH POLICY & SERVICES	3.5	29/87
Rheumatology	RHEUMATOLOGY	5.5	7/34
Rheumatology International	RHEUMATOLOGY	4	16/34
Seminars in Arthritis and Rheumatism	RHEUMATOLOGY	5	10/34
Statistics in Medicine	MATHEMATICAL & COMPUTATIONAL BIOLOGY	2	33/67
Surgery for Obesity and Related Diseases	SURGERY	3.1	50/213
Thorax	RESPIRATORY SYSTEM	10	7/66
Thrombosis Research	PERIPHERAL VASCULAR DISEASE	7.5	9/68
Trials	MEDICINE, RESEARCH & EXPERIMENTAL	2.5	99/136
Value in Health	ECONOMICS	4.5	69/380

(b) Conference Proceedings

Total 103: 34 oral presentations, 69 poster presentations

1. **Harrison M**, Dang H, Blitz S, Law M, Bansback N. Mandatory Biologic-Biosimilar Switching in British Columbia Did Not Result in Unintended Increases in Other Types of Healthcare Resource Utilization. Health Services Research Australia and New Zealand 13th Health Services Research Conference, Brisbane 4th December 2024. (Oral)
2. Cheng V, Amiri N, Ellis U, Cragg JJ, **Harrison M**, Proulx L, De Vera MA. Pregnancy Outcomes of Biosimilars and Non-TNF Inhibitor Biologic Disease-Modifying Antirheumatic Drugs: A Scoping Review. American College of Rheumatology, Washington DC, 16th November 2024. (Poster)
3. **Harrison M**, Dang H, Blitz S, Law M, Bansback N. Have switching policies led to increased healthcare resource utilization and cost? Evidence from British Columbia. Canadian Association for Health Services and Policy Research (CAHSPR), Ottawa, 14th May 2024. (Poster)
4. Bansback N, Law M, Clement F, Tadrous M, Blitz S, **Harrison M**. How Mandatory Switch Policies have Influenced the Uptake of Biosimilars in British Columbia. Canadian Association for Health Services and Policy Research (CAHSPR), Ottawa, 14th May 2024. (Poster)
5. Dang H, Blitz S, **Harrison M**, Law M, Bansback N. Have switching policies led to increased healthcare resource utilization and cost? Evidence from British Columbia. Centre for Health Services and Policy Research Conference March 2024, Vancouver BC. (Poster)
6. Bansback N, Law M, Clement F, Tadrous M, Blitz S, **Harrison M**. How Did a Mandatory Switch Policy Influence the Uptake of Adalimumab Biosimilar and Other TNF Inhibitors? American College of Rheumatology 2023. Washington DC, USA, November 14, 2023. (Poster)
7. **Harrison M**, McClellan A, Bansback N, Cheng L, Clement F, Tadrous M, Law MR. The impact of the first universal biosimilar switching policies for inflammatory arthritis in North America on uptake and spending. Japan College of Rheumatology 67th Annual Scientific Meeting (JCR2023). Fukuoka, Japan. 24th April 2023. (Oral).
8. McClellan A, Bansback N, Cheng L, Clement F, Tadrous M, Law MR, **Harrison M**. How Did a Mandatory Switching Policy for Biosimilars in Canada Impact Uptake and Spending? American College of Rheumatology Annual Scientific Meeting. Philadelphia, USA. 11th November 2022. (Oral)
9. Trenaman L, Guh D, McGrail K, Karim ME, Sawatzky R, Bryan S, Li L, Parker M, Wheeler K, **Harrison M**. Longitudinal patterns of health care costs among high-cost users: An application of group-based trajectory modelling to large administrative data. Society for Medical Decision-Making Annual Conference. Seattle, USA. 25th October 2022. (Poster)
10. Bansback N, **Harrison M**. Making decisions about clinical trial design: predicting participation rates in patient populations. Society for Medical Decision Making 44th Annual North American Meeting, Seattle, USA. 24th October 2022. (Oral)
11. Trenaman L, **Harrison M**, Hoch J. What is a star worth to Medicare beneficiaries? A discrete choice experiment of hospital quality, travel distance, and out-of-pocket cost. Society for Medical Decision Making 44th Annual North American Meeting, Seattle, USA. 24th October 2022. (Oral)
12. Bansback N, **Harrison M**. Predicting participation in clinical trials to inform design choices. 6th International Clinical Trials Methodology Conference 2022. Harrogate, UK. 5th October 2022. (Oral)
13. Kaal KJ, McGrail K, **Harrison M**, McBride M. Healthcare utilization and frequency of physician visits among survivors of childhood and adolescent cancer and population comparators in British Columbia (BC), Canada. 54th Congress of the International Society of Pediatric Oncology. Barcelona, 2022.
14. **Harrison M**, Aguilar M, Laba T-L, Munro S, Burch T, Beckett J, Kaal KJ, Bansback N, Hudson M. Involving Patients in the Design of Randomized Clinical Trials. 43rd Society for Clinical Trials Annual Meeting in San Diego. 2022. (Oral)
15. Metcalfe RK, **Harrison M**, Singer J, Lewis M, Lee T, von Dadelzen P, Magee LA, Bansback N. Integrating patient values into clinical trials using a patient-centred composite endpoint: a case study using the control of hypertension in pregnancy study (CHIPS) trial. 43rd Society for Clinical Trials Annual Meeting in San Diego. 2022. (Oral)
16. McClellan AR, Cheng L, Bansback N, Clement F, Tadrous M, **Harrison M**, Law MR. Biosimilar infliximab and etanercept use among individuals living with inflammatory arthritis and psoriasis: An interrupted time series analysis. Centre for Health Services and Policy Research Conference March 31st 2022, Vancouver BC. (Poster)

17. Bilin NK, Bansback N, Shojania K, Guh D, **Harrison M**. Patient referrals from primary care to rheumatology in British Columbia, Canada. Centre for Health Services and Policy Research Conference March 31st 2022, Vancouver BC. (Poster)
18. Bilin NK, Bansback N, Shojania K, Puil L, **Harrison M**. Improving the efficiency of patient referrals to rheumatology care: A scoping review of triage approaches from primary care. Centre for Health Services and Policy Research Conference. March 31st 2022, Vancouver BC. (Poster)
19. McClean AR, Law MR, Bansback N, Cheng L, Clement F, Tadrous M, **Harrison M**. Cost impact of switching to biosimilar infliximab and etanercept in British Columbia. Canadian Rheumatology Association Conference. 3rd February 2022, Online. (Poster)
20. Aguiar M, Apantaku G, Healy T, Grogan J, **Harrison M**. You talk we listen: advancing health economics methods for rural and remote health research by gathering local communities' knowledge and experiences in health care decision making. BC Rural Health Exchange. Online. 8th November 2021. (Oral)
21. McClean AR, Law MR, Bansback N, Cheng L, Clement F, Tadrous M, **Harrison M**. Uptake of biosimilar infliximab and etanercept in British Columbia. 2021 Annual Meeting of the American College of Epidemiology. Online. 9th September 2021. (Poster)
22. Apantaku G, Aguiar M, Kaal KJ, McDonald PJ, Hiricu V, Harrison M, Illes J. Developing attributes for a discrete choice experiment for novel neurotechnologies for pediatric drug-resistant epilepsy. National Institutes of Health BRAIN Meeting. 16th June 2021. Washington DC (Virtual). [Poster]
23. Illes J, Hrinco V, McDonald P, Connolly M, **Harrison M**, Ibrahim G, Naftel R, Chiong W, Udwardia F, Ribary U. Factors Guiding Choice of Novel Neurotechnological Interventions for Pediatric Drug Resistant Epilepsy: Physician and Caregiver Perspectives. Accepted for American Academy of Neurology, March 2021. (Oral)
24. Trenaman L, **Harrison M**, Hoch J. Patients' perspectives on value in Medicare's Hospital Value-based Purchasing Program: A pilot study. Accepted for Society for Medical Decision Making North American Meeting, October 2020. (Oral).
25. Aguiar M, Apantaku G, Munro S, Kaal KJ, Kur J, De Vera M, Koehn C, Patrick P, Shojania K, Teo M, **Harrison M**. Patients, Nurses and Rheumatologists' Perspectives on a Multidisciplinary Care Intervention in British Columbia. Accepted for Society for Medical Decision Making North American Meeting, October 2020. (Oral + Poster).
26. Aguiar M, Apantaku G, Kaal KJ, McDonald P, Illes J, **Harrison M**. Mapping Physician Decisions for Neurotechnologies for Pediatric Drug-Resistant Epilepsy: A Formative Qualitative Research Approach to Developing Attributes for a Discrete Choice Experiment. Accepted for Society for Medical Decision Making North American Meeting, October 2020. (Oral + Poster).
27. Metcalfe R, **Harrison M**, Singer J, Magee L, Bansback N. How and How Often Do Patient Decision Aids Address Emotion? A Review of Pregnancy Related Decision Aids. Accepted for Society for Medical Decision Making North American Meeting, October 2020. (Oral + Poster).
28. Aguiar M, Laba T-L, Munro S, Burch T, Kaal J, Bansback N, **Harrison M**. A Patient Oriented Research (POR) Approach to Design Early Phase Clinical Studies: Using a Discrete Choice Experiment to Understand the Preferences of People with Scleroderma for Stem Cell Transplant. Accepted for Society for Medical Decision Making North American Meeting, October 2020. (Oral + Poster).
29. Aguiar M, **Harrison M**, Thomas G. A model-based economic evaluation of psychedelic-assisted psychotherapy in British Columbia (PAP). Canadian Association for Health Services and Policy Research, Saskatoon. May 28th 2020. (Poster)
30. Kaal KJ, **Harrison M**, McBride M, McGrail K. Patient-sharing and cost of care among survivors of childhood, adolescent and young adult cancer. Centre for Health Services and Policy Research (CHSPR) 2020 32nd annual health policy conference, Vancouver BC. March 5th 2020 (Poster)
31. Aguiar M, **Harrison M**, Thomas G. A model-based economic evaluation of psychedelic-assisted psychotherapy in British Columbia. Centre for Health Services and Policy Research (CHSPR) 2020 32nd annual health policy conference, Vancouver BC. March 5th 2020 (Poster)
32. Duncan R, De Vera M, Shojania K, McGrail K, Koehn C, Law M, **Harrison M**. Evaluating the Impact on Access of the Introduction of Multidisciplinary Care for People With Complex Rheumatic Disease in British Columbia. Canadian Rheumatology Association Annual Scientific Meeting, Victoria, BC. February 27th 2020 (Poster)
33. Aguiar M, Munro S, Kaal KJ, Apantaku G, Shojania K, Patrick P, Kur J, Shaw J, Teo M, **Harrison M**. Perspectives on the implementation of a multidisciplinary conference fee code for community-based patients with rheumatic disease in BC (RHEUM-NURSE). Canadian Rheumatology Association Annual Scientific Meeting, Victoria, BC. February 27th 2020 (Poster)

34. Aguiar M, Burch T, Beckett J, Munro S, Kaal KJ, Laba T-L, Bansback N, Hudson M, **Harrison M**. Understanding the preferences of people with scleroderma regarding stem cell transplant: a patient-oriented approach to inform the design of early phase clinical studies. Canadian Rheumatology Association Annual Scientific Meeting, Victoria, BC. February 27th 2020 (Poster).
Awarded Top Rated Abstract
35. **Harrison M**, Duncan R, De Vera M, Shojania K, McGrail K, Koehn C, Law M. Evaluating the impact of introducing nurse-supported consultations on access to rheumatology care in British Columbia, Canada. Health Services Research Australia and New Zealand. Auckland, December 6th 2019 (Oral)
36. **Harrison M**, Burch T, Beckett J, Aguiar M, Munro S, Kaal KJ, Laba T-L, Bansback N. A patient-oriented approach to incorporate preferences into the design of clinical studies: stem cell transplant for scleroderma (Oral). Health Services Research Australia and New Zealand. Auckland, December 6th 2019 (Oral)
37. Sigurdson S, **Harrison M**, Pearce A, Richardson H, Brundage M: Localized prostate cancer patients' preferences for hypofractionated EBRT: Discrete choice experiment pilot study. Canadian Association of Radiation Oncology Conference, Halifax, October 3rd 2019 (Poster)
38. Burch T, Beckett J, Aguiar M, Munro S, Kaal J, Laba T-L, Bansback N, **Harrison M**. Considering shared decision-making in the design of clinical studies: methodological insights on approaching people with scleroderma in British Columbia. Accepted for: International Shared Decision Making Conference (ISDM) 2019 July 7-10 2019, Quebec City, Canada (Oral).
39. Aguiar M, Munro S, Burch T, Kaal J, Laba T-L, Bansback N, **Harrison M**. Considering shared decision-making in the design of clinical studies: methodological insights on approaching people with scleroderma in British Columbia. Accepted for: International Shared Decision Making Conference (ISDM) 2019 July 7-10 2019, Quebec City, Canada (Oral).
40. Kaal KJ, Aguiar M, Harrison M, McDonald P, Illes J. The Clinical Research Landscape of Neuromodulation for the Treatment of Pediatric Drug Resistant Epilepsy. Canadian Neuromodulation Society Conference, Iqaluit 2019. (Oral)
Julia Kaal (trainee) was awarded a travel award (\$2000).
41. Aguiar M, Munro S, Burch T, Kaal J, Laba T-L, Bansback N, **Harrison M**. A patient-oriented approach to inform the design of clinical studies: methodological insights on approaching people with scleroderma in British Columbia. Accepted for: Vancouver Health Economics Methodology Meeting, June 14th 2019. (Poster)
42. Kaal KJ, McGrail K, McBride M, **Harrison M**. A network analytic approach to assessing care coordination among survivors of childhood, adolescent and young adult cancer. Accepted for: Vancouver Health Economics Methodology Meeting, June 14th 2019. (Poster)
43. Duncan R, De Vera M, Law M, Shojania K, McGrail K, Koehn C, **Harrison M**. The impact of nurse-supported consultations to improve access to rheumatology care in British Columbia. Accepted for: Vancouver Health Economics Methodology Meeting, June 14th 2019. (Poster)
44. Kaal KJ, Aguiar M, **Harrison M**, McDonald P, Illes J. The clinical research Landscape of Neurotechnological intervention in the treatment of pediatric Drug resistant Epilepsy. National Institutes of Health (NIH) 2019 BRAIN Initiative® Investigators Meeting, Washington DC, April 12 2019. (Poster)
45. Kaal KJ, McGrail K, McBride M, **Harrison M**. A network analytic approach to assessing care coordination among survivors of childhood, adolescent and young adult cancer. The Centre for Health Services and Policy Research (CHSPR) 31st Annual Health Policy Conference, Vancouver, March 2019. (Poster)
46. Duncan R, De Vera M, Law M, Shojania K, McGrail K, Koehn C, **Harrison M**. Evaluating nurse-supported consultations to improve access to rheumatology care in British Columbia. The Centre for Health Services and Policy Research (CHSPR) 31st Annual Health Policy Conference, Vancouver, March 2019. (Poster)
47. Kaal KJ, Hudson M, Bansback N, **Harrison M**. Health Care Providers' Perceptions Regarding Barriers in the Implementation of Preventive Therapies in Rheumatoid Arthritis. Canadian Rheumatology Association Annual Scientific Meeting, Montreal, February 2019 (Poster)
48. Metcalfe R, Magee L, Singer J, Harrison M, Lee T, Hutfield A, Bansback N. A qualitative inquiry into women's preferences for treatment of hypertension in pregnancy. International Society of Obstetric Medicine. Amsterdam, October 2018 (Poster).
49. Kaal KJ, Bansback N, Anis A, **Harrison MJ**. Patient-Physician Communication about Medication Costs in Rheumatoid Arthritis. American College of Rheumatology, Chicago October 2018. (Oral)
50. Tsao N, Milbers K, Lo C, Martinusen D, Marin J, Leung M, Harrison M, The Impact of Framing of Costs on Estimates of Willingness to Pay for Aspects of Treatment in Chronic Kidney Disease. Society for Medical Decision Making, Montreal, October 2018. (Poster)

51. **Harrison MJ**, Han P, Rabin B, Bell M, Kay H, Spooner L, Peacock S, Bansback N. Communicating Uncertainty in Cancer Prognosis: A Review of Web-Based Prognostic Tools. Society for Medical Decision Making, Montreal, October 2018. (Poster)
52. Tsao NW, Milbers K, Haag H, **Harrison M**. "Like we have a choice": A qualitative study of patient's views on epoetin biosimilars for anemia of chronic kidney disease. Drug Information Association Global Annual Meeting, Boston, 25th June 2018. (Poster)
Awarded 2nd Place Prize: Best Research Poster.
53. Bansback N, Hudson M, Koehn C, Laba TL, **Harrison M**. How to design clinical trials to be more patient oriented: an example from preventative treatments for rheumatoid arthritis. European League Against Rheumatism – Amsterdam 16 June 2018 (Poster)
54. **Harrison M**, Hudson M, Koehn C, Bansback N. Predicting uptake of treatments to assist health technology assessment: A case study in preventive treatments for rheumatoid arthritis. Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, Halifax, April 2018. (Poster)
55. **Harrison M**, Bansback N, Spooner L, Koehn C, Hudson M. Preventing Rheumatoid Arthritis (Pre-RA): Preferences of Potential Recipients, Patients, and Health Care Professionals for Preventative Treatment. Canadian Rheumatology Association Annual Scientific Meeting, Vancouver, February 2018 (Oral)
Official evaluation of this presentation from a sample of 38 audience members rated it as follows: The content was clear (4.2/5), relevant (4.1/5), and offered appropriate opportunities for audience interaction (4.1/5). All respondents rated the content of my presentation as scientifically valid and balanced (100%), free from indicators of undue industry bias (100%), and free from indicators of undue personal/other bias (100%).
56. **Harrison M**, Spooner L, Hudson M, Koehn C, Finckh A, Bansback N. Preventing Rheumatoid Arthritis: North American Perspectives of Patients and First-Degree Relatives on the Risk of Developing the Disease and of Potential Preventative Interventions. American College of Rheumatology, San Diego, November 2017. (Oral)
57. **Harrison M**, Hudson M, Bansback N. The Impact of the Accuracy of Predicting Risk of Developing a Disease on the Preferences of People Around Preventative Treatment Options. Society for Medical Decision Making, Pittsburgh, October 2017. (Poster)
58. Ho H, Janjua N, **Harrison M**, McGrail K, Law M, British Columbia Hepatitis Testers Cohort Team. Adherence to sofosbuvir and ledipasvir-sofosbuvir in British Columbia. 68th Annual Meeting of the American Association for the Study of Liver Diseases, Washington DC, October 2017. (Poster)
59. **Harrison M**, Bansback N, Spooner L, Milbers K, Koehn C, Hudson M. Preventing rheumatoid arthritis: general population perspectives on the risk developing the disease and on potential preventative interventions in a pilot study. International Health Economics Association – Boston 10 July 2017. (Oral)
60. **Harrison M**, Bansback N, Spooner L, Milbers K, Koehn C, Hudson M. Preventing rheumatoid arthritis: a general population pilot study on perspectives of the risk of developing the disease and potential preventative treatment. Canadian Association for Health Services and Policy Research – Toronto 25 May 2017 (Poster)
61. Spooner L, Milbers K, Munro S, Tsao N, Hudson M, Koehn C, Bansback N, **Harrison M**. The perspectives of patients, their first degree relatives, and rheumatologists around preventative treatments for rheumatoid arthritis. European League Against Rheumatism – Madrid 15 June 2017 (Poster)
62. **Harrison M**, Bansback N, Spooner L, Milbers K, Koehn C, Hudson M. Preventing rheumatoid arthritis: a general population pilot study on perspectives of the risk of developing the disease and potential preventative treatment. European League Against Rheumatism – Madrid 15 June 2017 (Poster)
63. **Harrison M**, Milbers K, Hudson, Bansback N. Is there evidence for concordance between patients and physicians for aspects of treatments that matter most? A review of discrete choice experiments. Society for Medical Decision Making 2016. Vancouver, Canada, October 23-26, 2016. (Poster)
64. **Harrison M**, Bell M, Spooner L, Pompeo A, Han PKJ, Bansback N. How is uncertainty in risks and benefits presented in patient decision support interventions? A review. Society for Medical Decision Making 2016. Vancouver, Canada, October 23-26, 2016. (Oral)
65. Gavan S, **Harrison M**, Barton A, BRAGGSS, Hyrich K, Isaacs J, Morgan A, Wilson A, & Payne K. Identifying factors which influence the selection of anti-TNF treatment in patients with rheumatoid arthritis in England. ISPOR 21st Annual International Meeting, Washington, DC, USA. May 21-25 2016. (Poster)
66. Bansback N, **Harrison M**, Dixon W, Han P. Influence on Treatment Decision Making of Providing Numerical Ranges of Side-Effect Risks. American College of Rheumatology 2015. San Francisco, USA, November 6-11, 2015. (Oral)
67. **Harrison M**, Marra CA, Bansback N. Describe Treatments As 'new' or 'old' at Your Peril: Influences on Patient Decision Making. American College of Rheumatology 2015. San Francisco, USA, November 6-11, 2015. (Poster)

68. **Harrison M**, Marra CA, Bansback N. What is the impact of describing treatments as 'new'? Society for Medical Decision Making 2015. St Louis, USA, October 21-24, 2015. (Poster)
69. Bansback N, **Harrison M**, Han P. Aversion to ambiguity about risk of treatment harms influences decision making and varies by level of risk and ambiguity. Society for Medical Decision Making 2015. St Louis, USA, October 21-24, 2015. (Poster)
70. **Harrison M**, Marra CA, Bansback N. Preferences for new treatments diminish in the face of ambiguity. International Health Economics Association World Congress. Milan, Italy, July 12-15, 2015.(Oral)
71. **Harrison M**, Marra CA, Bansback N. Preferences for new treatments diminish in the face of ambiguity. International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting. Philadelphia, PA, USA, May 16-20, 2015 (Poster).
72. **Harrison M**, Marra CA, Shojania K, Bansback N. Societal preferences for rheumatoid arthritis treatments. Evidence from a discrete choice experiment. Canadian Rheumatology Association 2015. Quebec City, Canada, February 4-7, 2015. (Poster)
73. Meacock R, Kristensen S, Harrison M, Sutton M. Adoption of HQID in England was cost-effective in the short term. Academy Health Annual Research Meeting – San Diego, USA, 2015. (Poster).
74. **Harrison M**, Marra CA, Shojania K, Bansback N. Societal preferences for rheumatoid arthritis treatments. Evidence from a discrete choice experiment. American College of Rheumatology 2014. Boston, USA, November 15-19, 2014. (Poster presentation with oral presentation to poster tour)
75. Meacock R, **Harrison M**, McElhone K, Abbott J, Haque S, Bruce I, Teh L-S. Mapping the disease-specific LupusQoL to the SF-6D. American College of Rheumatology 2014. Boston, USA, November 15-19, 2014. (Poster)
76. Bansback N, **Harrison M**, Marra CA. Does introducing imprecision around probabilities for benefit and harm influence the way people value treatments? Society for Medical Decision Making 2014. Miami, FL, USA, October 18-22, 2014. (Poster)
77. Meacock R, **Harrison MJ**, McElhone K, Isenberg D, Ferenkeh-Koroma A, Ahmad Y, Bruce IN, Shelmerdine J, Gordon C, Peers K, Griffiths B, Maddison P, Akil M, Abbott J, The L-S. Exploratory mapping of the lupus QoL to the SF-6D. International Society for Pharmacoeconomics and Outcomes Research European Meeting 2012. Berlin, Germany, November 3, 2012. (Poster).
Nominated for best poster presentation award.
78. Bujkiewicz S, Sutton AJ, Cooper NJ, Thompson JR, Spiegelhalter DR, **Harrison MJ**, Symmons DPMS, Abrams KR. Multivariate meta-analysis of surrogate endpoints in health technology assessment: A Bayesian approach. International Society for Clinical Biostatistics 2012. Bergen, Norway, August 10, 2012. (Oral)
79. Meacock R, **Harrison MJ**, Hay C. Modelling the right dose for high-cost drugs: Application to immune tolerance induction in infants with severe haemophilia A. Nordic Health Economists' Study Group Meeting 2012. Kuopio, Finland, August 15, 2012.
80. **Harrison MJ**, Jacob I, Sutton M, Radford J, Renehan A. Modelling capacity for more resource-intensive services – An application of discrete event simulation to flexible sigmoidoscopy for colorectal cancer. European Conference of Health Economics 2012. Zurich, Switzerland, July 18, 2012. (Oral)
81. Nikolova S, **Harrison MJ**, Sutton M. Does waiting time influence the effectiveness of surgery? Evidence from the national PROMs dataset. Health Economists' Study Group 2012. Oxford, UK, June 25, 2012.
82. **Harrison MJ**, Dusheiko M, Doran T, Gravelle H, Sutton M, Roland M. The impact of financial incentives for improvements in the quality of primary care on emergency hospital admission rates. International Health Economics Association Conference 2011. Toronto, Canada, July 10, 2011.
83. **Harrison MJ**, Dusheiko M, Doran T, Gravelle H, Sutton M, Roland M. Does better management of chronic conditions in general practice reduce emergency hospital admissions? Health Economists' Study Group Meeting 2011. Bangor, North Wales, UK, June 29, 2011.
84. **Harrison MJ**, Reeves D, Fullwood C, Bower PJ, Kennedy AP, Rogers AE. What factors influence patient engagement with the Expert Patients Programme course: Secondary analysis of data from a randomized controlled trial. International Conference on Support for Self Management of Health 2010. Stirling, Scotland, UK, May 11, 2010.
85. Reeves D, **Harrison MJ**, Fullwood C, Bower PJ, Kennedy AP, Rogers AE. Predicting who will benefit from an expert patients programme self-management course. International Conference on Support for Self Management of Health 2010. Stirling, Scotland, UK, May 11, 2010.
86. Pain CE, **Harrison MJ**, Symmons DPM, Foster HE, Baildam EM. Workforce planning in paediatric rheumatology in the United Kingdom (UK). British Society of Rheumatology Meeting 2010. Birmingham, UK, April 21, 2010.

87. Pain CE, Harrison MJ, Symmonds DPM, Foster HE, Baildam EM. Workforce planning in paediatric rheumatology in the United Kingdom (UK). American College of Rheumatology Conference 2009. Philadelphia, PA, USA, October 17, 2009.
88. Barta Z, **Harrison MJ**, Wangrangsimakul T, Shelmerdine J, Teh L-S, Patrick M, Edlin H, Dale N, Ahmad Y, Bruce IN (2009). Health-related quality of life, smoking and subclinical atherosclerosis in women with Systemic Lupus Erythematosus. National Congress of Physical Medicine and Rehabilitation, Budapest, Hungary, 2009
89. **Harrison MJ**, Boonen A, Tugwell P, Symmons DPM. Same question, different answer: a comparison of global health assessments using VAS scales. EULAR, Copenhagen 2009 (Poster). *Ann Rheum Dis* 2009.
90. **Harrison MJ**, Boonen A, Tugwell P, Symmons DPM. Same question, different answer: a comparison of global health assessments using VAS scales. British Society for Rheumatology, Glasgow 2009 (Poster). *Rheumatology (Oxford)* 2009;48(Suppl. 1):i110.
91. **Harrison MJ**, Watson K, Bansback N, Verstappen S, Symmons DPM. The validity of estimating EQ-5D scores from the HAQ and SF-36. British Society for Rheumatology, Glasgow 2009 (Poster). *Rheumatology (Oxford)* 2009;48(Suppl. 1):i111-112.
92. **Harrison MJ**, Farragher TM, Clarke AM, Bunn D, Manning S, Symmons DPM. Functional outcome is associated with personal and area level socioeconomic inequalities in inflammatory polyarthritis patients. American College of Rheumatology, San Francisco 2008 (Oral presentation). *Arthritis Rheum* 2008;58(9, (supplement)):S915-S916
93. **Harrison MJ**, Lunt M, Bansback N, Verstappen S, Watson K, Symmons DPM. The validity of estimating EQ-5D and SF-6D utility values from the HAQ. American College of Rheumatology, San Francisco 2008 (Poster). *Arthritis Rheum* 2008;58(9, (supplement)):S204
94. **Harrison MJ**, Deighton C, Symmons DPM. Patterns of provision and perceived job threat in the UK rheumatology consultant workforce: results from the BSR/arc Workforce Register. British Society for Rheumatology, Liverpool 2008 (Poster). *Rheumatology (Oxford)* 2008;47(Suppl. 2): II120.
95. **Harrison MJ**, Davies L, Bansback NJ, Symmons DPM. The comparative ability of the EQ-5D and SF-6D health utility measures to assess change in patients with rheumatoid arthritis. Health Economists' Study Group, Norwich 2008.
96. Health status in inflammatory arthritis patients with "worse than death" EQ-5D scores. **Harrison MJ**, Davies L, Bansback NJ, McCoy MJ, Hassell A, Symmons DPM. American College of Rheumatology, Boston USA 2007 (Poster). *Arthritis Rheum* 2007;56(9, (supplement)):S594-S595.
97. Bansback NJ, **Harrison MJ**, Brazier J, Davies L, Kopec J, Marra CA, Symmons DPM, Anis A. Health state utility values in rheumatic diseases – a review. EULAR Barcelona 2007 (Poster). *Ann Rheum Dis* 2007;66(Suppl. 2):256.
98. **Harrison MJ**, Davies L, Bansback NJ, McCoy MJ, Hassell A, Symmons DPM. Why do patients with rheumatoid arthritis often score "states worse than death" on the EQ-5D? British Society for Rheumatology, Birmingham 2007 (Oral presentation). *Rheumatology (Oxford)* 2007;46(Supplement 1):i8.
99. **Harrison MJ**, Davies L, Bansback NJ, Symmons DPM. The comparative measurement properties of the EQ-5D and SF-6D health utility measures in patients with rheumatoid arthritis. Arthritis and Rheumatism 2006. American College of Rheumatology Washington DC 2006 (Poster). *Arthritis Rheum* 2006;54(9, (supplement)):S106.
100. **Harrison M**, Morley K.D., & Symmons D. BSR/arc consultant workforce register - 2003-2005. British Society for Rheumatology Glasgow 2006 (Poster). *Rheumatology (Oxford)* 45, 1131-1132. 2006.
101. **Harrison M**, Tricker, K., Davies, L., Dawes, P., Scott, D., Mulherin, D. *et al.* (2005). Social deprivation: an important predictor of response to treatment in a clinical trial situation. British Society for Rheumatology Birmingham 2005 (Poster). *Rheumatology (Oxford)* 2005 Mar;44:150-151.
102. **Harrison MJ**, O'Hare AE, Campbell H, Adamson A, McNeillage J. Autistic Spectrum Disorders in Lothian, Scotland, First Study of Prevalence with use of the capture recapture technique. Sheffield 2004 (Oral presentation). *Developmental Mental Medicine Child Neurology* 2004; 98(46):19.
103. **Harrison MJ**, Tricker, K. J., Davies, L., Roberts, C., & Symmons, D. P. M. The impact of social deprivation on health related quality of life and functional disability in patients with established rheumatoid arthritis. British Society for Rheumatology Edinburgh 2004 (Poster). *Rheumatology (Oxford)* 2004 Apr 1;43(suppl_2):ii84.

(c) Reports

1. Humphrey N, Hennesey A, Lendrum A, Wigelsworth M, Turner A, Panayiotou M, Joyce C, Pert K, Stephens E, Wo L, Squires G, Woods K, **Harrison M**, Calam R. Evaluating the efficacy of the Promoting Alternative Thinking Strategies (PATHS) curriculum in promoting social and emotional wellbeing among children in primary school: a cluster randomised controlled trial and process evaluation. National Institute for Health Research (NIHR) UK
2. Barlow A, Wigelsworth M, Lendrum A, Pert K, Joyce C, Stephens E, Wo L, Squires G, Woods K, Calam R, **Harrison M**, Turner A, Humphrey N. Promoting Alternative Thinking Strategies (PATHS): Evaluation report and Executive summary. Report for the Education Endowment Foundation (UK). June 2015.

2. NON-REFEREED PUBLICATIONS**(a) Reports and Papers**

1. Apantaku G, Teo M, **Harrison M**. Patient, Rheumatologist and Nurse Perspectives on Multidisciplinary Rheumatology Care Assessments in BC. Canadian Rheumatology Association Journal. 31(2): 7. 2021 [SA]
2. Biln NK, Bansback N, Shojania K, Puil L, **Harrison M**. Protocol for a scoping review of triage approaches for patient referrals from primary to rheumatology care. OSF. 2021
3. McGrail K, Ahuja M, Huang X, Law M, Wong S, **Harrison M**, McGregor M, Berg S, Bryan S, Mitton C. An Evaluation of the Accelerated Integrated Primary and Community Care Initiatives. Centre for Health Services and Policy Research. April 2019.
<https://open.library.ubc.ca/cIRcle/collections/facultyresearchandpublications/52383/items/1.0380854>
4. **Harrison M**, Bansback N, Bryan S. Unlocking the Potential of Patient-Reported Outcome Measures (PROMs) to Support Health Care System Sustainability: Scoping Phase. Report to the Institute for Health System Transformation and Sustainability. 2017.
5. Kolhatkar A, Cheng L, Chan F, **Harrison M**, Law MR. The Impact of Medication Reviews by Community Pharmacists. Report for the BC Ministry of Health. 2016.
6. Kolhatkar A, Cheng L, Chan F, **Harrison M**, Law MR. The Impact of Medication Reviews by Community Pharmacists. Report for the Canadian Institute of Health Information. 2016.
7. **Harrison MJ**. Does better management of chronic conditions in general practice reduce emergency hospital admissions? Report for the Department of Health (UK). 2011.
8. Hyrich K, Lunt M, Davies R, **Harrison MJ**, Watson K, Symmons D, on behalf of the BSR Biologics Register. The British Society for Rheumatology Biologics Register: Updated Analysis on Sequential Use of Anti-TNF Therapies in Patients with Rheumatoid Arthritis. Report for the National Institute for Health and Clinical Excellence (NICE) (UK). 2009.

(b) Blogs

1. Bansback N & **Harrison M**. Rethinking how we design clinical studies. The Methods Section: BC SUPPORT Unit. <https://methodssection.ca/home/rethinking-how-we-design-clinical-studies>

3. BOOKS**(a) *Authored***

1. Aguiar M, Apantaku G, Grogan J, Healy T, **Harrison M**. Through A Northern Lens: A Community View on Northern Health and Wellbeing in Northern BC. Editor: Morris B. Lake Shannon Publishing. 1st edition, June 2022. ISBN: 978-0-9867107-4-2
<https://www.pluralbc.org/book>

(b) *Edited***(c) *Chapters***

1. Johnson D, Dragojlovic N, Kopac N, Chen Y, Lenzen M, le Huray S, Pollard S, Regier D, **Harrison M**, George A, Carenini G, Ng R, Lynd L. EXPECT-NLP: An Integrated Pipeline and User Interface for Exploring Patient Preferences Directly from Patient-Generated Text. In Multimodal AI in Healthcare: A Paradigm Shift in Health Intelligence, published in: Studies in Computational Intelligence (Springer). 2022.
2. **Harrison MJ**. Inflammatory Arthritis EQ-5D and SF-6D. Encyclopedia of Quality of Life Research. AC Michalos (Editor). 2012.

4. PATENTS**5. SPECIAL COPYRIGHTS****6. ARTISTIC WORKS, PERFORMANCES, DESIGNS**

1. Through A Northern Lens: A Community View on Northern Health and Wellbeing in Northern BC. Exhibition and Open Studio. June 4th - 19th 2022. Omineca Arts Centre, 369 Victoria Street, Prince George, Canada.
<https://www.pluralbc.org/exhibitions>; <https://www.omincaartscentre.com/events/2022/6/18/plural-photovoice-exhibition-amp-book-launch>
2. Through A Northern Lens: A Community View on Northern Health and Wellbeing in Northern BC. Exhibition and Open Studio. June 30th - July 2nd 2022. Valemount Community Hall, 201 Gorse St, Valemount, BC, Canada. <https://www.pluralbc.org/exhibitions>
3. Through A Northern Lens: A Community View on Northern Health and Wellbeing in Northern BC. Exhibition and Open Studio. July 3rd – 5th 2022. Robson Valley Community Centre, 441 Columbia St, McBride, BC, Canada. <https://www.pluralbc.org/exhibitions>

7. OTHER WORKS**8. WORK SUBMITTED (including publisher and date of submission)****9. WORK IN PROGRESS (including degree of completion)**